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SUMMARY
Bladder cancer is the fourth most common malignancy in the Western world. In 
the UK there are 12,500 new cases each year and 5,000 deaths annually. In 80% of 
patients the disease is diagnosed in its early superficial stage (Ta, T l) and 20% in its 
deep stage (invasive) T2-T4. Of the superficial group, 20% will never have recurrence, 
50% will have one or more superficial recuiTcnces within 1 -2 years and 30% will 
develop invasive disease, most of whom will die from bladder cancer. This means that 
these patients need lifelong medical vigilance involving periodic internal inspection of 
their bladder. These constitute a significant proportion of the general urological 
consultants workload due to high prevalence and recurrent nature.
This has fuelled the continuous investigation of factors to predict those patients 
in whom who are likely to recur and those likely to progress. In identifying those 
patients most likely to recur and progress, one might significantly reduce mortality and 
also help to highlight those patients in whom intensive follow-up is not required.
It is recognised that both innate and adaptive immunity are involved in the 
immune response to bladder tumours. There is increasing evidence that cell-mediated 
immunity plays a key role in tumour progression of patients with bladder cancer. The 
infiltration of bladder tumours with tissue lymphocytes has been demonstrated and 
suggests the presence of a local active immune defence of the host against bladder 
tumour. In addition, some components of innate immunity have been found to be of 
prognostic value in bladder cancer. However, the relationship between the tumour 
proliferation, the systemic and local inflammatory responses and outcome remains 
unclear.
The thesis involved three cohorts of patients with transitional cell carcinoma of 
the urinary bladder. The first cohort consisted of patients in whom either pre- and/or
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post resection systemic inflammatory response (C-reactive protein) measurement 
together with other clinieopathological variables were related to outcome. The second 
cohort consisted of patients in which pre-operative measurement of C-reactive protein 
was related to tumour proliferation (measured by Ki-67), local inflammatory reaction 
measured by infiltration of CD4+ and CD8+ and tumour associated macrophage 
(CD68+), micro vessel density (CD34+) and COX-2 expression in the tumour tissue.
The third cohort consisted of patients in whom C-reactive protein measurements were 
related to circulating cytokines/chemokines concentration involved in the regulation of 
the T-lymphocytes and other immune responses to the tumour.
The results of the first study were that on univariate analysis, stage (p<0.001 ), 
grade (p<0.001) and elevated C-reactive protein pre-operatively (p<0.05) and post- 
operatively (p<0.01) were significantly associated with cancer-specific survival. On 
multivariate analysis of patients who had a pre-operative C-reactive protein 
determination, stage (p<0.008), grade (p<0.017) and pre-operative C-reactive protein 
(p<0.035) were independently associated with cancer-specific survival. Those patients 
with an elevated pre-operative C-reactive protein concentration had a mean cancer- 
specific survival of 65.5 months compared with 103.7 months in those patients with a 
C-reactive protein concentration in the normal range (<10 mg/1). These findings would 
suggest that C-reactive protein is associated with disease progression and poor survival 
in patients with transitional cell carcinoma of the urinary bladder.
The results of the second study were that on univariate analysis, stratified by 
stage, C-reactive protein (p<0.05), increased Ki-67 labelling index (p<0.05), increased 
tumour associated macrophage (p<0.01), increased tumour microvessel density 
expression (p<0.001) increased COX-2 expression (p<0.05) and adjuvant therapy 
(p<0.01) were associated with poorer cancer-specific survival. On multivariate analysis
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of these significant factors, stratified by stage, only C-reactive protein (p-0.004), 
increased tumour associated macrophage (p<0,001) and adjuvant therapy (p<0.01) were 
independently associated with poorer cancer-specific survival. These findings would 
suggest that tumour macrophage infiltration is an important local inflammatory 
response associated with disease progiession and poor sumval in patients with 
transitional cell carcinoma of the urinary bladder.
The results of the third study were that, using multiple cytokine analysis 
technology, ThO-type cytokines/chemokines (lL-6, IL-7, IL-8, IL-15 and GM-CSF), 
Thl-type cytokines/chemokines (IL-2, interferon-gamma and TNF-alpha) and Th2-type 
cytokines/chemokines (lL-4, IL-5, IL-10 and IL-13) measurement showed median 
plasma concentrations below the limit of detection (5pg/ml) irrespective of their C- 
reactive protein concentrations, stage and grade. However, maerophage/monocyte-type 
cytokines/chemokines (MlP-1 alpha, MIP-1 beta and MCP-1) and eosinophils-type 
cytokines/chemokines (EOTAXIN) had detectable median plasma concentrations but 
also were not associated with elevated C-reactive protein concentrations, stage and 
grade. These findings were inconclusive because of the low concentrations measured in 
the plasma. Further work is required to obtain reliable measurements in the plasma of 
patients with transitional cell carcinoma using multiple cytokine analysis technology.
Therefore, the results suggest that an elevated C-reactive protein concentration 
would be a useful marker of poor cancer-specific survival in patients with transitional 
cell carcinoma of the urinary bladder, in addition to tumour-based factors, and enable 
the stratification of patients for study and follow-up. Furthennore, that tumour 
macrophage infiltration is also an important predictor of outcome and is directly 
associated with C-reactive protein concentration and may be, through IL-6, an important 
mediator of C-reactive protein and the systemic inflammatory response.
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1-INTRODUCTION
1.1 Incidence and mortality
Bladder caneer is the fourth most common cancer, after prostate, lung and 
colorectal cancer in men, accounting for 6% of all cancer cases, with 7,581 new cases 
diagnosed per year in men and a crude rate per 100,000 population of 26.5 for the UK 
population and 20 for Scotland. In women, it is the eighth most common cancer 
accounting for over 2% of all cancers with nearly 3,000 new cases diagnosed per year 
and a crude rate per 100,000 population of 10 for the UK population. In Scotland, 
nearly 500 men and 250 women were diagnosed with bladder cancer in 2001. There is a 
1:30 risk of developing bladder cancer in men compared with 1:79 in women 
(Cancerstats, 2002).
Bladder cancer is rarely found incidentally at autopsy (Kishi et al, 1981) and the 
means by which it is diagnosed (cystoscopy and biopsy) have not changed for the last 
six decades. Therefore, it is unlikely that the increased incidence is due to technological 
developments or changes in health care practice.
Bladder eancer is the seventh most common cause of cancer death in UK men 
with nearly 3,200 deaths for the year 2003, and the tenth in women with 1,700 deaths 
for the year 2003. In Scotland, nearly 150 men and 100 women died due to bladder 
cancer. Eighty-six percent of male deaths and 90% of female deaths occur after the age 
of 65 years. Between 1979 and 2000, the mortality rates for 50-59 year old men fell by 
55% and for women of the same age by 45% (Cancerstats, 2002).
Bladder cancer can occur in any age, even in children, but it is usually a disease 
of the middle-aged and elderly. The median age at diagnosis for transitional cell
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carcinoma is 69 for men and 71 for women. However, the incidence increases directly 
with age and mortality is higher in the elderly (Cancerstat, 2002).
Suiwival of bladder cancer patients depends mostly on the depth of the tumour 
penetration in-to the bladder wall, in addition to other factors including multiple tumour 
foci, grade and tumour type. Patients with superficial disease (70%) have an excellent 
prognosis with 5-year survival rates between 80-90% compared with approximately 
50% in patients with muscle-invasive disease (Zieger et ah, 1998).
It is likely that the incidence of bladder eancer will continue to increase with the 
aging of the UK population. In contrast, there has been a decrease in mortality rate 
from bladder cancer. Whether the decrease in mortality is due to a fundamental change 
in the biology of the disease, alteration in risk factors for different types, better 
treatment, earlier diagnosis or a combination of all theses factors together remains 
uncertain.
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1.2. Aetiology
Despite the identification of industrial teratogens and other carcinogens, the 
aetiology of bladder tumours in the majority of patients remains unexplained mainly 
due to the long latency period. This mechanism is multi factorial; it involves carcinoma- 
promoting factors (environmental influences, smoking, abuse of analgesics, genetic 
disposition) which support a malignant transfonnation that occurs in multiple steps.
1.2.1 Occupational Exposure
In Geiinany, in 1895, Ludwig Rehn showed the connection between papillary 
bladder tumours and an exposure to aniline dyes. In 1938, Hueper succeeded in proving 
the exogenous carcinogen: he showed that bladder carcinomas in dogs can be induced 
through exposure to beta-naphthylamine. More recently it has been estimated that 
approximately 35% of bladder cancers in men have an occupational origin, in 
occupations in which chemicals of the aryl hydrocarbon group are used (Cole et al 
1972). These include benzedrine, a- and (3-napththylamines, aminobipenyl, and 
orthotolidine, with a long latent period of between 30-50 years (Case et al, 1954).
Other occupations reported to be associated with an increased risk of bladder 
cancer include those of autoworkers, painters, tiuck drivers, drill press operators, leather 
workers, metal workers and machinists; also, those occupations involved with organic 
chemicals such as dry cleaners, paper manufactures, rope and twine workers, dental 
technicians, barbers and beauticians, physicians, workers in apparel manufacturing and 
plumbers (Momson, 1984).
The connection between the development of bladder carcinoma and individual 
genetic disposition of the enzymes N-acetyItransferase-2, (which, among other things, 
converts aromatic amines, dmgs and caffeine) is under debate. There are two so called
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human phenotypes; the fast and slow acetylator. In slow acétylation of the oxidative 
metabolism, for example, of aromatic amines, there are many steps in which aryl 
nitrenium ions are produced that allow bladder tumours to occur. The percentage of 
eaeh phenotype is markedly varied in different ethnic giuups. In Europe, 50-60% are 
slow acetylators, whereas in China the number is 7.6% (Golka et ah, 2002).
1.2.2 Cigarette smoking
Zeegers and associates performed a meta-analysis of 43 epidemiologic studies 
on smoking characteristics for bladder cancer risk and concluded that cuiTent cigarette 
smokers have an approximately threefold higher risk of urinary tract cancers than non- 
smokers (Zeegers et al., 2004). Although tobacco smoke condensates contain a mixture 
of chemicals, the molecular mechanisms are likely to be based on exposure to the 
carcinogens 4-aminobiphenyl and 2-naphthylamine in cigarette smoke. The risk is 
associated with the number of cigarettes smoked, the duration of smoking, and degree 
of inhalation. Ex-smokers have reduced incidence of bladder cancer compared with the 
active smoker (Bryant et ah, 1988). The reduction of the risk to that of the non-smoking 
population takes about 20 years after stopping smoking. This is far longer compared to 
the reduction in risk of cardiovascular disease and lung cancer.
p53 gene mutations are related to tobacco-smoke carcinogens and the frequency 
of smoking increases the extent of DNA damage (Bemardini et al.,2001).
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1.2.3 Age and sex
The male: female ratio of age-standardised rates fell from 4.0:1.0 in 1975 to 
3.5:1.0 in 2001. This discrepancy between the genders in the numbers of new cases of 
bladder cancer is perhaps not surprising because during the past 30 years women have 
joined the male workplace and have changed habits that have exposed them to both 
industrial and environmental carcinogens (Edward et al 1997).
1.2.4 Race
According to the SEER data from the United States, African Americans, 
especially women, have a 60 to 100% higher mortality from bladder cancer than do 
their white counterparts. Several explanations for the higher mortality among such racial 
differences are: more aggressive disease, low socio-economic status, elapsed time from 
symptoms to onset of treatment, occupational exposure, smoking and difference in 
metabolism of toxic substances (Madeb and Messing, 2004).
1.2.5 Chronic cvstitis and other infections
Cystitis-induced bladder cancer is usually associated with severe, long-tenu 
infection. Chronic cystitis due to the presence of indwelling catheter or calculi is 
associated with an increased risk for bladder cancer. Delnay and co-workers studied 208 
patients with paraplegia with long-tenn catheter with 7 years follow-up and found that 
a total of 17 patients were identified with malignancy, including 10 with squamous cell 
carcinoma, 5 with transitional cell carcinoma and 2 with adenocarcinoma (Delnay et 
ah,1995).
Infestation of the bladder with Schistasoma haematobium also appears to be 
related to the development of bladder cancer, often squamous cell carcinoma. In Egypt,
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where schistomaiasis is endemic among men, squamous cell carcinoma of the bladder 
(bilharzias bladder eancer) is the most common malignancy (Badawi et ah, 1995). Viral 
infection has also been blamed in relation to bladder cancer, LaRue and co-workers 
(1995) reported that as many as 35% of bladder tumours have evidence of the human 
papillomavims HPV. However, recent studies suggest that HPV is unlikely to play a 
major role in the development of bladder TCC (Youshya et ah, 2005).
The mechanism of such carcinogenicity is most likely related to the formation of 
nitrate and N-nitroso compounds in the bladder from microbial metabolism of normal 
urinary constitution (Delnay et ah, 1995).
1.2.6 Hereditv
No epidemiologic evidence exists for a hereditary cause of bladder cancer, 
although familial clusters of bladder cancer have been reported. Of these, lynch 
syndrome II, an inherited syndrome associated with colorectal cancer without polyposis 
and with extra-colonic cancer site, has been described in which four male siblings 
developed transitional cell carcinoma of the urinary bladder (Lynch et al, 1990)
Other reported cases of bladder cancer have been attributed to pelvic irradiation 
(Sella et al, 1989) and cyclophosphamide (Tuttle et al, 1988).
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1.3 Pathology
1.3.1 Tumour staging
Transitional cell carcinoma has been traditionally characterised as either 
superficial or invasive. Superficial tumours are the most common initial presentation 
(70 to 75%; Heney, 1992). However, there are 3 stages of superficial disease. These 
include “flat” carcinoma in situ confined to the urothelium, papillary tumours confined 
to the mucosa (Ta) and papillary or nodular tumours with invasion into the lamina 
propria (Tl).
Carcinoma in situ (Tis) replaces the urothelial layer with high-gi*ade, anaplastic 
cells and appears as flat red patches in the bladder and may be difficult to distinguish 
from the changes of chronic infection or inflammation (Witjes, 2004). Data from the 
literature suggest that these lesions have high recurrence rates, a high likelihood of 
invasion, and are associated with poor cancer survival (Eble et al., 2004). These lesions 
are frequently multifocal and may present with other papillary lesions. Urinary cytology 
study is useful in detecting non-visible lesions because the exfoliated cells in these cases 
exhibit severe dysplasia.
Stage Ta lesions account for approximately 70% of superficial TCC. 
Histologically, these papillary tumours are composed of a branching fibrovascular core 
and a mucosa greater than 8 cell layers with features of anaplasia. Ta lesions are 
typically low-grade.
Stage Tl bladder carcinoma has demonstrated lamina propria invasion. They 
have a high percentage of progression to more advanced disease and tend to be high-
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grade tumours (Heney, 1992). The malignant potential of these lesions separates them 
clearly from Ta and carcinoma in situ lesions. Many have argued that these tumours 
should not be considered “superficial” because they demonstrate a natural history more 
consistent with muscle-invasive cancer especially if they have a high-grade G3, since, 
many patients with pathologic Tl carcinoma treated with bacille Calmette-Guérin 
(BCG) will still progress to muscle-invasive disease (Manoharan and Soloway, 2005). 
Further stage subdivision has been proposed for Tl tumours according to the depth of 
lamina propria invasion (Figure 1.1).
Currently, pathologic staging of bladder cancer is usually carried out according 
to the 2002 American Joint Committee on Cancer/International Union Against Cancer 
TNM staging guidelines (Eble et al., 2004).
TNM staging svstem for bladder carcinoma (6^ '^  edition)
Primary tumour (T)
The suffix (m) is added to the appropriate category to indicate multiple tumours and the 
suffix (is) to indicate associated carcinoma in situ.
TX Primary tumour cannot be assessed 
TO No evidence of primary tumour 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ “fiat tumour”
Tl Tumour invades sub epithelial connective tissue 
T2 Tumour invades muscle
T2a tumour invades superficial muscle (inner half)
T2b Tumour invades deep muscle (outer half)
24
T3 Tumour invades perivesical tissue 
T3a microscopically 
T3b macroscopically 
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, and 
abdominal wall
T4a Tumour invades prostate, utems or vagina.
T4b Tumour invades pelvic wall or abdominal wall.
Regional lymph nodes (N)
Nx Cannot be assessed
NO No metastasis in regional node
N 1 Metastasis in one node 2cm or less in diameter
N2 Metastasis in one node 2-5 cm in diameter or multiple nodes not > 5 cm in diameter. 
N3 Metastasis in one node > 5 cm in diameter 
Distal metastasis (M)
Mx Cannot be assessed 
MO No distal metastasis 
M 1 Distal metastasis
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T2b
T2a T3a
T3b
T4b
m
Figure 1.1 T staging o f bladder cancer
Tis, carcinoma in situ; Ta, tumour involves mucosa only; T l, tumour invades 
through lamina propria; T2a, tumour invades into superficial detrusor muscle; T2b, 
tumour invades into deep detrusor muscle; T3a, tumour microscopically invades 
perivesical tissue; T3b, tumour macroscopically invades perivesical tissue and fonns 
extravesical mass; T4a, tumour invading prostate/utems/vagina; T4b, tumour fixed to 
pelvic wall (adapted h'om Colquhoun and Mellon, 2002).
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1.3.2 Tumour grading
Urinary bladder tumours are graded traditionally as well-differentiated (Gl), 
moderately-differentiated (G2), or poorly-differentiated (G3) according to the degi'ee of 
cellular anaplasia (Busch et ah, 2002). There is a strong correlation between tumour 
stage and grade. Most well-differentiated tumours are superficial and most poorly- 
differentiated tumours are invasive.
Considerable disagi eement has been shown in the interpretation of histological 
grade between pathologists (Humphrey, 2004). Tumour gi-ading is such a controversial 
issue that the initial grading in 1974 was replaced with the cunent version in 1999. 
Furtheniiore, the new 2004 giading system could help to naiTow the differences 
especially in G2 tumours. The chief difference in this latest grading system compared 
with the WHO 1999 scheme is that rather than three grades of papillary urothelial 
carcinoma, there are two (low-giade and high-grade) in the WHO 2004 classification. 
The authors of the WHO 2004 system cite genetic studies that suggest there are "two 
major subtypes of urothelial neoplasms which might have a distinctly different clinical 
course": genetically stable tumours that include most non-invasive low-giade 
carcinomas and genetically unstable non-invasive high-grade carcinomas and invasive 
careinomas. Currently, these genetic differences and specific molecular markers, such 
as cytokeratin 20, p53, p63, CD44, FGFR3, and Ki-67 hold promise for the future but 
are not in routine use in gi'ading of urothelial proliferations (Eble et al, 2004, 
Humphrey, 2004).
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1.4 Clinical Features of transitional ceil carcinoma of the urinary bladder
Early symptom recognition in bladder tumour is a key to better prognosis. The 
most common sign of bladder cancer is haematuria. Approximately 80% of all patients 
with TCC will be diagnosed with either gi'oss or microscopic haematuria. In one study 
of 1000 consecutive patients evaluated for gi'oss painless haematuria, 15% were found 
to have bladder cancer (Turner et ah, 1977). Microscopic haematuria (usually 
asymptomatic) is a much more eommon presenting symptom than gross haematuria. 
Previous studies have shown that between 2 to 22% of patients with microscopic 
haematuria will be found to have a malignancy (Carson et ah, 1979). Other presenting 
symptoms are due to bladder irritability with dysuria, frequency, and urgency being 
seen in around 20% of patients. In these instances the patients will often have invasive 
lesions or CIS (FaiTow et ah, 1977). Other patients may present with recurrent urinary 
tract infections, loin pain secondary to an obstructed ureter, sterile pyuria, or as an 
incidental finding at cystoscopy. Symptoms of advanced disease include bone pain 
fi'om bone metastasis or flank pain from retroperitoneal metastasis or urethral 
obstruction.
In the majority of patients, clinical examination will usually be nonnal due to 
the superficial nature of the disease. Occasionally in advanced disease an abdominal or 
pelvic mass may be palpable. Hepatomegaly, lymphodema from occlusive pelvic 
lymphadenopathy and supraclaviclar lymphadenopathy are signs of metastatic disease 
(Walsh et al., 2002).
Transitional cell carcinomas have a tendency to recur after excision (Figure 1.2); 
such recuiTence could be similar to the initial tumour or the tumour could progress to 
more advanced tumour (grade and stage). Although the teim "recurrence" is used, most 
of the subsequent tumours arise at different sites from the original lesion and the time
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intei*val could be many years. Recurrent tumours reflect new tumours in some cases, 
and in other instances, they share the same clonal abnormalities as the initial tumour and 
represent a true recurrence of the initial lesion as a result of shedding and implantation 
of the original tumour cells (Colquhoun and Mellon, 2002).
Bladder cancer diagnosed
20%8 0 % .
Non-m uscle-i n VQ s i ve Muscle-invasive
jTa and Tl} (T2-T4)
50%^
1 No
1 recurrence
. 5 0 %
recurrence
60% -70%
Superficial
recurrence
20%-40%
Progression ro 
muscle-invasive 
disease
Good prognosis Poor prognosis
Figure 1.2 The natural history of bladder cancer (adapted from Colquhoun and 
Mellon, 2002)
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1.5 Treatment of transitional cell carcinoma of the urinary bladder
All patients with bladder tumours should initially undergo transurethral resection 
of the tumour. A bimanual examination of the bladder should be performed both before 
and after the resection in order to stage the tumour clinically. Random biopsies of 
apparently normal bladder distant from the tumour can be taken to look for the presence 
of associated carcinoma in situ. Further management is then largely based on the stage 
and grade of the tumour.
1.5.1 Superficial disease
Management of patients with Ta and Tl tumour will take into account the risk of 
recurrence and progression, side effects and cost-effectiveness. pTa tumours, comprise 
35% of all bladder cancers and are usually well-differentiated (Gl). Less than 5% of 
pTa tumours progi^ess to invasive disease and the 10 year survival of around 96%. In 
the United Kingdom pTl tumours comprise approximately 30% of bladder cancers. 
Prognosis is slightly worse than with pTa tumours, with a 10 year suiwival of around 
65% (Zieger et a l, 1998). Using the above parameters, superficial bladder tumour can 
be divided into:
• Low-risk tumours: single, Ta, G l, < 3 cm diameter.
• Intermediate: Ta-1, G 1-2, multimodal, >3 cm diameter, all other tumours.
• High-risk tumours: T l, G3, multimodal or highly recurrent, CIS (TIS).
For the low-risk tumours, treatment consists of intravesical chemotherapy post- 
TURBT: a single dose of intravesical instillation of mitomycin or epirubicin within 24 
hours post-tumour resection has been found to reduce recuiTence rate by approximately 
50%. In intermediate risk tumours a further instillation is required. It is recommended 
that tumours with a higher risk of recun-ence should be treated with a 4-8 week course
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of bladder instillations. In the case of carcinoma in situ or multiple recurrences it is 
recommended intravesical BCG therapy be given (Alexanrdroff et ah, 1999). . BCG 
therapy has been found to be effective in preventing disease progression and reducing 
the number of tumour recuiTence ((Sylvester et al., 2002, Han and Pan, 2006).
1.5.2 Invasive bladder cancer
Invasive bladder cancer caiTies a poor prognosis with transurethral resection 
alone; the 5 year survival is less than 50%. However, if  patients are carefully selected 
for treatment, 10 year survival can reach up to 75% (Walsh et ah, 2002). Tumours 
should be ideally solitary, papillary, less than 3 cm in size, and a biopsy of the bladder 
wall deep to the tumour must be clear if  this approach is adopted. Since this does not 
apply in most cases, a more aggressive approach is necessary including either external 
beam radiation or cystectomy with urinary diversion or a neobladder constiuction.
1.5.3 Disseminated disease
Distant métastasés are mainly located in liver (approximately 40%), lung 
(approximately 40%) and bone (approximately 20%). More than 50% of all patients 
with invasive tumours also have distant métastasés (Walsh et ah, 2002). The treatment 
of disseminated bladder cancer is essentially palliative as patients have a median 
survival of only 6 months. Multi-agent chemotherapy using methotrexate, vinblastine, 
docorubicin and cisplatin (M-VAC) can double the median survival with approximately 
15% of patients surviving 2 years, but it canies a significant morbidity in patients who 
may already be very weak (Roberts, 2005).
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1.5.4 Follow-up after TURB
A superficial bladder tumour has a high tendency to recur after resection (Figure 
1.2). Several causes have been suggested for this high recurrence rate; incomplete 
resection, implantation at traumatised sites in the bladder or rapid growth of epithelial 
malignancy. Therefore, an early check cystoscopy preferably under general anaesthetic 
3 months after resection is now usual in almost all cases of superficial bladder cancer. 
The findings at the initial 3 month check cystoscopy give a useftil guide to prognosis. If 
no recurrence is identified at 3 months, approximately 80% of patients will have no 
further recurrence. On the other hand, of those patients noted to have a recurrence at 3 
months, approximatlylO% will have no further recun-ence (Ali-El-Dein et ah, 2003).
The frequency of later cystoscopies should be adapted to the prognostic factors 
of the tumour. In low-risk tumours with no recurrence at 3 months, a follow-up 
cystoscopy can be delayed until 9 months later and then yearly up to 5 years. In 
contrast, patients with high-risk tumours, a cystoscopy every 3 months during the first 2 
years remains the most commonly adopted follow-up schedule (Hall et al., 1994). 
Cystoscopy should then follow every 4 months until the third year, every 6 months 
thereafter for up to 5 years and then yearly. The schedule of follow-up in the 
inteimediate group lies in between. With any recurrence, the schedule of cystoscopies 
is re-started from the beginning (Hall et al., 1994).
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1.6 Immunotherapy
Immunological treatment for bladder cancer falls into two general categories: 
passive and active. Passive immunotherapy involves the direct administration of 
molecules or cells to a patient and requires no direct involvement of the patient immune 
system. Active immunotherapy attempts to enhance the host immune response. Passive 
and active immunotherapy may be non-specific or specific in nature. Non-specific 
immunotherapy induces inflammation or otherwise amplifies an already present 
immune response, e.g. bacillus Calmette-Guerin (BCG). In contrast, specific 
immunotherapy requires tumour specific antigen recognition by T cells and/or 
antibodies (Walsh et ah, 2002).
Passive immunotherapy: non-specific, consists of the administration of 
cytokines that indirectly affect tumour growth by stimulating cytotoxic T cells or by 
acting directly on tumour cells e.g. IFN gamma against superficial bladder cancer 
(Giannopoulos et al, 2003). On the other hand, specific immunotherapy, target tumour 
antigen-specific T-lymphocytes or antibodies produced by B-lymphocytes are 
adoptively transferred into a recipient, H creep tin, the mAh specific for HER-2/neu used 
in the treatment of breast cancer, has recently been studied in bladder cancer (Latif et al, 
2004, Hauser-IGonberger et al,, 2006). Active immunotherapy: non-specific, which 
stimulates the innate inflammatory response, this consists of mainly BCG and 
cytokines. Active specific immunotherapy is the vaccination of patients to induce long- 
lived, tumour-specific immunity.
1.6.1 BCG
BCG is an attenuated live strain of mycobacterium bovis. In 1976, Morales, 
Eidinger and Bruce were the first to report on successful treatment of superficial bladder
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cancer with BCG (Morales et al, 1976). Since then, BCG has become the treatment of 
choice for high-risk superficial bladder tumour. However, the mode of action has not 
been fully understood and it is believed to be immunological rather than a direct 
cytotoxic effect in that it activates macrophages and dendritic cells (Alexanrdroff et ah, 
1999).
Wide acceptance of BCG immunotherapy for bladder cancer, however, did not 
begin until the controlled study by the Southwest Oncology Group showed in 1980 that 
there were unequivocal benefits in terms of decreased recuiTence rate and increased 
median time to recurrence in patients given BCG immuno-prophylaxis after local 
surgery (Lamm et al., 1980). A recent meta-analysis of randomised clinical trials, 
investigating the effect of intravesical BCG and progression showed that BCG 
immunotherapy significantly reduced the risk of progression after transurethral 
resection in patients with superficial disease who receive maintenance treatment 
(Sylvester et ah, 2002). The authors suggest that BCG is the agent of choice for patients 
with intermediate and high-risk papillary tumours and those with carcinoma in situ.
More recently, Han and Pan (2006) in meta-analysis of randomised clinical trials 
concluded that intravesical BCG with maintenance treatment is effective for the 
prophylaxis of tumour recurrence in superficial bladder cancer, Furthennore, for 
patients with papillary carcinoma, they concluded that adjuvant intravesical BCG with 
maintenance therapy should be offered as the treatment of choice.
Standard treatment consists of BCG instillations given over a 6 week period. 
Complete remission is obtained in up to 70% of cases and half of patients will be 
disease-free at 5 years. Side effects of treatment with BCG are common, with about half 
the patients experiencing an increase in ftequency and dysuria. Maintenance therapy
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with booster cycles up to 36 months is advocated to prevent recurrence (Huncharek and 
Kupelnick, 2003).
1.6.2 Cvtokines
Interferons (IFN): IFNs are host-produced glycoprotein in response to antigenic 
stimuli and have multiple anti-tumour activities that act to mediate immune responses 
through antiviral, anti-proliferative and regulatory activities. The combination of 
interferon-alpha with bacillus Calmette-Guerin appears to result in remarkable synergy, 
affecting not only bladder tumours directly but also enhancing the immune response to 
bacillus Calmette-Guerin by orders of magnitude (O'Donnell, 2003). A recent national 
multi-centre phase II trial of the combination of BCG and interferon in 1,007 patients 
showed that although BCG plus IFN-alpha can be effective in both patients naive to 
BCG and those having BCG failure, certain patient and tumour characteristics influence 
durable response (Joudi et al., 2006).
Intravesical IL-2 has shown promise in the treatment of superficial bladder 
cancer (Den Otter et al., 1998). IL-12 has been shown to induce T-lymphocyte and 
natural killer cell proliferation/activation and production of IFN gamma. A phase I 
study has evaluated intravesical recombinant human IL-12 administration in patients 
with superficial bladder cancer (Weiss et ah, 2003).
1.6.3 COX-2 inhibitors
Mohammed and co-workers examined the potential anti-tumour effects of a 
COX-2 inhibitor in the canine model with invasive bladder cancer. All tumours 
positively immunostained for COX-2, and COX-2 inhibition therapy resulted in a 
statistically significant reduction in tumour volume in 12 of 18 animals, with an
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associated increased rate of apoptosis and decrease in PGE2 (Mohammed et ah, 2002). 
The clinical study of COX-2 inhibitors in bladder cancer is just underway, the BOXIT 
(Bladder COX-2 Inhibition Trial), which is a randomised phase III parallel-group multi­
centre double-blind placebo-controlled clinical trial in patients with transitional cell 
carcinoma of the bladder by giving Celecoxib for 2 years in addition to their standard 
treatment and assessing outcome after 3 years (Cancer Research UK).
1.6.4 Other immunotherapy
Bropirimine is an immuno-modulating agent considered to boost immunity in 
bladder cancer. Oral bropirimine has been shown to have anti-cancer activity in 
carcinoma in situ of bladder cancer. In a phase III European clinical study comparing 
55 BCG-naive patients randomised to either oral bropirimine (n=27) or BCG (n=28), 
the complete response rate was 92% and 100% with a mean duration of 12.6 months 
and 12.3 months respectively (Witjes et ah, 1999).
Keyhole-Limpet Hemocyanin (KLH) is an antigenic protein from the 
hemolymph of Megathura crenulata and a non-specific immuno-modulator, has shown 
efficacy in Ta and T l bladder cancer and CIS. Although less effective than BCG, it is 
less toxic and may have a role as an alternative biologic response modifier in treating 
superficial bladder cancer (Walsh et ah, 2002).
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1.7 Tumour growth and spread
There is considerable complexity with the process of tumour growth and 
metastasis. Not only tumour-based factors (intrinsic) but also host-based factors 
(extrinsic) play a role in this process. Although biomarkers can reflect activity in 
individual pathways, when a global assessment is made of tumour growth then single 
markers are of limited value. Carcinogenesis is cuiTently considered to be divided into 
initiation, promotion and progression (Walsh et al., 2002).
1.7.1 Tumour-based factors (intrinsic)
The ability of tumour cell populations to expand in number is deteimined not 
only by the rate of cell proliferation but also by the rate of apoptosis (progi'ammed cell 
death). It is believed that acquired resistance toward apoptosis is a hallmark of most 
and perhaps all types of cancer (Hanahan and Weinberg, 2000). Tbe cellular 
homeostasis is defined by a balance between the destructive and proliferative processes 
of cells. Cell death seiwes as a local defence mechanism to remove potentially haimflil 
damaged cells, caused by cytotoxic inflammatory response and is a lifelong programme 
that genetically regulates the cell destruction process.
Apoptosis appears to be triggered through receptor-ligand interaction, mainly 
the fas-fas legand by binding of the Fas-ligand expressed on the cytotoxic T- 
lymphocyte to Fas expressed on the target cell. This will trigger a cascade of changes 
and Fas interacts with proteins in the death pathway leading to activation of the caspase 
enzyme. This in turn activates caspase-activated DNAse which migrates into the 
nucleus leading to chromosome de-fragmentation and consequently a complete loss of 
the cell.
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In a recent study of 147 patients with superficial bladder cancers the apoptotic 
index (the number of apoptotic cells divided by the total number of tumour cell 
population) and Ki-67 labelling index were assessed. The apoptotic index and Ki-67 
labelling index appear to correlate with tumour grade and stage. In addition, apoptotic 
index appears to correlate with tumour size and grade (Gonzalez-Campora et ah, 2006).
The behaviour of bladder cancer to date is not predictable and there has been a 
huge interest in identifying the molecular characteristics that determine a tumour's 
behaviour, both to determine the prognosis of an individual tumour and to identify new 
therapeutic targets. There are clinical-pathological markers such as tumour stage (Able 
et al., 1988), grade of anaplasia (Pauwells et ah, 1988), tumour size (Hellsten et al.,
1983, multiplicity (Pocock et ah, 1982) and gi'owth pattern (Kern, 1984).
Recently, the European Organisation for Research and Treatment of Cancer 
(EGRTC) analysed the results collected over 30 years of 2596 patients with superficial 
bladder cancer (Tis, Ta, T l) with a median follow-up of 3.9 years and a maximum 
follow-up of 14.8 years. 1240 (47.8%) had recurrence 313 (12.1%) in the first 3 
months, with progi'ession amongst those with recurrence of 279 ( 10.7%). During the 
follow-up period 853 (32.9%) died and of these 262 (10.1%) were bladder cancer- 
related. On multivariate analysis, prior recuiTence, number of tumours, tumour size, T 
stage (Tis, Ta, T l) and gi*ade (G l, G2, G3) were all associated with tumour recurrence 
and progression. The most important of the prognostic factors for progi'ession were the 
tumour stage, grade, and the presence of carcinoma in situ which reflect the biological 
aggressiveness of the disease. The authors also suggest that the molecular markers such 
as p53, Ki-67 labelling index and COX-2 have some promise; however, they concluded 
that these have not been sufficiently validated for routine use at this time (Sylvester et 
al., 2006).
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Potential tumour-based prognostic factors that can be classified into the 
following groups: proto-oncogenes/oncogenes, tumour suppressor genes, cell cycle 
regulators and angiogenesis-related factors (Figure 1.3).
Caspase-8
RbBax
Hypoxia growth factors Effectorcascapes
IDNA damage
VEGFproteases Ras 8 0 S
ÜV light, radicals,
chemical mutagens, TGF|),IFNY
Figure 1.3 The complex oncogenic pathways in the established cancer cell. (Adapted 
h'om Duggan et ah, 2004)
EGFR, epithelial growth factor receptor; ECM, extracellular matrix; VEGF, 
vascular endothelial growth factor; TGF, transforming growth factor; IFN, interferon.
Proto-oncogenes/oncogenes
Oncogenes are altered normal genes that encode for malignant phenotype, 
primarily by peimitting cells to escape from normal mechanism of growth control.
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Pathological expression of EGFR leads to uncontrolled cell proliferation through 
increased angiogenesis and reduced apoptosis. However, the mechanism by which 
EGFR expression is associated with poor prognosis is not entirely clear, although there 
is some evidence linking EGFR-stimulated activation of activator protein-1 transcription 
factor with induction of matrix metalloproteinase activity (Wells, 2000). Several 
investigators have shown a positive association between over-expression of epidermal 
growth factor receptor (EGFR) and high-grade, high-stage bladder cancer and poor 
suiwival (Neal et ah, 1990, Lipponen et al., 1994).
Tumour suppressor genes
These are genes responsible for coding for proteins that regulate cell growth, 
DNA repair or apoptosis. Deletion or inactivation of these tumour suppressor genes 
could encourage unregulated growth or failure to direct DNA-damaged cells to 
programmed death. This will lead to uncontrolled proliferation of genetically altered 
clones. Three suppressor gene loci are found to be associated with bladder cancer; they 
are p53 (on chromosome 17p), the retinoblastoma gene Rb gene, (on chromosome 13q) 
and the gene on chromosome 9 at p i5 and p i6.
P53 is the most frequent altered gene in human cancer (Hall and McCluggage, 
2006). The normal p53 protein (wt p53) is located on the 17p 13,1 locus and has 
several functions; acting as transcription factor that suppresses cell proliferation and 
directing the DNA-damaged cell toward apoptosis before DNA replication S-phase o f 
cell cycle occurs. P53 mutation has been associated with genomic instability leading to 
progressive development of flirther mutation. Bladder cancers with p53 abnonnalities 
appear to behave more aggi-essively (Cordon-Cordo, 1995). Tl tumours that express 
wild-type (normal) p53 are reported to have a progression rate of around 2.5% per year
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compared with 20 % per year in tumours expressing mutant p53. However, a meta­
analysis by Schmitz-Drager and co-workers showed that approximately half of the 
studies, which include p53 in multivariate analyses, confirmed its value as a prognostic 
marker of progression in Tl bladder cancer. In addition, in only 2 of the 7 studies in 
muscle-invasive bladder cancer was p53 confinned as an independent prognostic 
marker of disease progression (Schmitz-Drager et ah, 2000). Indeed, a recent meta­
analysis concluded that the evidence is not sufficient to routinely use p53 as a marker of 
outcome in patients with bladder cancer (Malats et ah, 2005).
Cell cvcle regulators
The expression of the human Ki-67 protein is strictly associated with cell 
proliferation. During inteiphase, the antigen can be exclusively detected within the 
nucleus, whereas in mitosis most of the protein is relocated to the surface of the 
chromosomes. The fact that the Ki-67 protein is present during all active phases of the 
cell cycle (Gl, S, G2 and mitosis), but is absent from resting cells (GO), makes it an 
excellent marker for deteiinining the so called growth fraction of a given cell 
population. Little is known about the function of this protein. However, we do know 
that it is vital for cell proliferation, since removal of pICi-67 using antisense nucleotides 
prevents cell proliferation (Schluter et ah, 1993).
A number of studies have shown that Ki-67 is an independent prognostic marker 
of bladder cancer progression and recurrence in multivariate analysis. For example, in 
159 patients with Ta or T l bladder cancer, a high Ki-67 index (>18%) and multifocality 
were independently associated with increased recurrence, progression and poor survival 
(Santos et ah, 2003). Similarly, a study of 114 patients with bladder cancer showed that 
Ki-67 expression was an independent prognostic factor associated with poor disease-
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specific survival in multivariate analysis (Popov et al., 1997). These studies consistently 
indicate that elevated Ki-67 expression is a promising marker for increased recurrence 
and progression in superficial bladder cancer.
A study for p21 and p53 expression in bladder cancer patients showed that p21 
labelling was an independent predictor of cancer survival (Chatterjee et al 2004). In 
120 consecutive cases of urothelial carcinoma, p27 levels were significantly higher in 
low-grade, superficial, papillary, and slowly-proliferating tumours (Korkolopoulou et 
ah, 2000).
Cyclin D1 is a positive regulator o f the cell cycle. In a multicenter study of 207 
patients with superficial (Ta or T l) bladder cancer, the cyclin D1 expression level was 
an independent predictor of tumour recurrence. However, it did not provide additional 
prognostic information on disease progression (Liukkonen et al., 2000). A study using 
a tissue micro-array of 2317 specimens from 1842 patients with bladder cancer staged 
Ta through to T3 demonstrated that low cyclin E expression was associated with poor 
overall survival in all patients but it had no prognostic impact independent of stage 
(Richter et al., 2000)
Angiogenesis-related factors
Cyclooxygenases (COX) are enzymes that are responsible for foimation of 
prostanoids (ineluding prostaglandins, prostacyclin and thromboxane). COX enzyme 
converts arachidonic acid to prostaglandin H2, the precursor of the series-2 prostanoids 
(Table 1.1). These are among the most important enzymes involved in the regulation of 
the immune response and play a key role in angiogenesis, the inhibition of apoptosis, 
and cell proliferation and motility (Figure 1.4).
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Expression
Functions
Inhibition
Cyclo-oxygenase-1
Constitutive
Found in all tissues
Housekeeping function in 
platelet, stomach, kidneys, 
and endothelium 
Aspirin and non-steroidal 
anti-inflammatory drugs
Cyclo-oxygenase-2
Constitutively expressed only in brain, lung, 
kidney
Rapidly induced in inflammatory tissue (1-3 h) 
Induced by cytokines and growth factors (IL- 
2,TNF-a)
Inflammatory process in macrophages, 
leucocytes, fibroblasts, and endothelium
Anti-inflammatory cytokines (IL-10), Aspirin, 
non-steroidal anti-inflammatory drugs and 
glucocorticoids.
Table L I  The function and production of cyclooxygenase enzymes (Adapted from 
Bjorkman, 1998)
Figure 1.4 shows the interactive relationship among cancer cells, endothelial 
cells and infiltrating inflammatory cells at the site of tumour. The prostaglandin pool is 
contributed to by all three different cell types and occasionally stromal cells. The 
positive feedback through prostaglandin receptors increases COX-2 expression and 
ensures the continued generation of prostaglandins. In the cancer cell, prostaglandin 
signalling also results in the production of multiple angiogenesis factors, through which 
they stimulate neovascular foraiation. In inflammatory cells, prostaglandin signalling 
stimulates the generation of pro-inflammatory molecules such as IL-2, which further 
recruits additional circulating monocytes and amplifies the inflammatory response. As a
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response to the increased levels o f prostaglandins, angiogenesis factors and pro- 
inflammatory molecules are believed to lead to endothelial cell proliferation, migration 
and stimulation o f vessel formation. These will provide additional nutrients for 
oncogenesis as well as a potential route for metastasis (Zha et al., 2004).
VEGF expression determined by in situ hybridisation was an independent 
prognostic factor for disease recurrence by multivariate analysis in 55 patients with 
muscle-invasive bladder cancer treated with neoadjuvant MVAC chemotherapy and 
radical cystectomy (Inoue et al. 2000).
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Figure 1.4 COX-2 in angiogenesis. (Adapted from Zha et al., 2004)
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1.7.3 Host factors detennining progi'ession in bladder cancer (extrinsic factors)
The host response to the changes from normal cell to tumour cell is complex and 
cioicial to tumour progression. Such a response appears to either act to kill the tumour 
cells or to enable the tumour cells to grow and spread.
Immune Surveillance
Immune suiweillance explains the mechanism by which the immune system 
keeps cancers from arising. The theory states that patrolling cells of the immune system 
provide continuing body-wide surveillance and eliminate foreign cells or cells that 
undergo cancerous transfonnation. This theory developed by a number of workers 
including Thomas (1959) and Burnet (1970) is consistent with a number of clinical 
observations. For example, cancer is rare in children and young adults, but appears more 
frequently with advancing age, when the efficiency of the immune system declines. In 
addition, most solid tumours were found to contain large numbers of lymphocytes, 
suggesting that the cellular immune system recognised the malignant neoplasm as 
foreign and attacked it (Algarra et al., 2004).
The connection between tumour growth and immunity is not new; in fact 
Virchow in 1863 noted leucoeytes in neoplastic tissues and made a connection between 
inflammation and cancer. He suggested that the “lymphoreticular infiltrate” reflected 
the origin of cancer at sites of chronic inflammation (Balkwill and Mantovani, 2001). In 
1909 Ehrlich showed that tumours transplanted to non-tumour bearing mice initially 
would grow, then shrink and disappear. He won the Nobel Prize in 1908 for his 
suggestion that antibodies could be used like “magic bullets” to treat all types of 
diseases!
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More recent observations also supporting the immune sui-veillance theory 
include the presence of tumour antigens and promotion of tumour gi'owth when the 
thymus is removed or when immunosuppressive dmgs are given (Baniyash, 2006).
The immune system recognises tumours and demonstrates its response to 
tumour antigens. Such recognition appears to be through Human Leucocyte Antigens 
(HLA). The Human Leucocyte Antigens (HLA) are a gioup of genes in the human 
major histoeompatibihty complex (MHC) on human chromosome 6 that encodes the 
cell-surface antigen-presenting proteins. Every organism has two sets of HLA genes, 
HLA class I and II. HLA class I molecules are found on almost every nucleated cell of 
the body while HLA class II molecules are found only on a few specialised cell types, 
including macrophages, dendritic cells and activated lymphocytes, all of which are 
antigen-presenting cells.
CD4'*' T-lymphocytes respond to tumour-associated antigens presented by MHC 
class II molecules (Robbins and Kawakami, 1996). Dendritic cells infiltrating the 
tumour bed and present in the draining lymph nodes are critical for the presentation of 
processed tumour antigen peptides to the lymphocyte and its activation (Schuler and 
Steinman, 1997). Tumour cells have been generally considered to be poor stimulators of 
lymphocyte due to the lack of expression of HLA class II molecules and their variable 
expression of HLA class I molecules. Both CDS'" and CDd"" T-lymphocytes can destroy 
tumour cells by the expansion of cytoplasmic granules containing the pore-fonning 
protein called perforin. This will result in plasma membrane dismption or by the up- 
regulation of Fas-ligand that can bind to Fas (on the tumours) to induce apoptosis. 
Cytokines are also important to tumour rejection. IFN-y produced by both CD4" and 
CDS'" lymphocytes is known to be critical; it leads to its activation of other effectors 
cells, such as macrophages, that are known to infiltrate the tumour (Brunda et al, 1995).
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Tumour Antigens
Most tumours are antigenic and on the cell surfaces there are many antigens. 
These are divided into; tumour-specific antigens (only present in the tumour cells) 
others are non-specific or tumour-associated antigen (found in the embryonic and very 
minor quantities in the nonnal tissues). However, to date none of these antigens have 
been shown to be specific to transitional epithelium, let alone its tumours.
Bladder Tumour Antigen (BTA) in the urine has been shown to detect bladder 
cancer. This has been identified as human complement factor H-related protein in the 
urine (Habuchi et al., 2005). Malignant transformation of urothelial cells appears to be 
associated with loss of ABH blood group antigen and enhanced Lewis X (Le^) antigen 
expression. The Le^ antigen seems to be expressed regardless of bladder cancer grade or 
stage (Golijanin et al., 1995).
How does immune surveillance break down?
There are many mechanisms which could explain the immune surveillance break 
down: impaired antigen presentation, where the recognition of tumour cells by T ceils, 
may be impaired due to defective antigen processing and presentation (Pawelec et al, 
1997, Seliger et al, 1997). Others involve the secretion of immunosuppressive products. 
These products may be secreted by the tumour cells themselves or by suiTounding 
inflammatory cell infiltrates. The primary inhibitory effect of IL-10 is believed to be 
related to its ability to down-regulate MHC class II expression on monocytes/dendritic 
cells, resulting in reduced antigen presentation (Uzzo et al, 2000). IL-10 may also 
directly block T cell growth and may inhibit the production of other pro-inflammatory 
cytokines such as IL-1, IL-6, IL-8, and TNF-a.
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The tumour cells secrete factors that stimulate angiogeuesis such as Vascular 
Endothelial Growth Factor (VEGF). VEGF can induce capillary growth into the tumour, 
supplying required nutrients and allowing for tumour expansion. Thus, angiogeuesis is a 
necessary and required step for transition from a small harmless cluster of cells, to a 
large tumour. Angiogeuesis is also required for the spread of a tumour or metastasis 
(Walsh et al., 2002).
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1.8 Inflammation and cancer
1.8.1 Introduction
Recently ehronic inflammation has been identified as a risk factor for cancer. 
Chronic activation of the immune system is, in itself, associated with the development 
of tumours such as schistosomiasis and bladder cancer (Badawi et al, 1995), human 
papilloma virus (HPV) and cancer (Munger , 2002), helicobacter pylori bacterial 
infection and gastric adenocarcinoma (Naumann, 2002), the hepatitis B virus, cinhosis 
and hepatocellular carcinoma (Hilleman, 2003). However, chronic inflammation, 
arising as a result of chronic exposure to a non-infective irritant, may also be associated 
with the development of malignant disease. Chronic bronchitis and emphysema due to 
cigarette smoking are recognised risk factors for the development of lung cancer 
(Mayne et al, 1999). Carcinoma of the gastro-oesophageal junction is associated with 
chronic oesophagitis, including BaiTctt’s oesophagus (McCann, 1999). Mesothelioma 
arises as a result of chronic exposure to asbestos fibres (Wagner et al., 1960). The 
association between chionic inflammatory bowel disease and cancer of the bowel is 
well established (Kirk and Clements, 1999).
This evidence would suggest that an inflammation environment would support 
tumour development. It may be that the inflammatory response due to tumour 
environment stress may generate a protective shield from the immune system. It has 
been recently demonstrated that the tumour microenvironment highly resembles an 
inflammation site, with significant advantages for the progession of tumour, including 
the effect of cytokines, chemokines, leucocytes, lymphocytes and macrophages 
resulting in both vasodilatation and neovascularisation for increased blood flow and the 
immunosuppression which contributes to the process of metastasis (Schwartsburd, 
2003).
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1.8.2 Inflammatory cells infiltrate in cancer 
T-Lymphocytes
T-lymphocytes are specific killer cells; their fonction is believed to be the lysis 
of tumour cells. There are two major types of T-lymphocytes:
• Helper T-lymphocytes (CD4+) activate macrophages, and also produce 
cytokines that induce the proliferation of B and T cells.
• Cytotoxic T-lymphocytes (CD8+) recognise tumour cells by using T-cell 
receptors to probe the surface of other cells
The receptors for T-lymphocytes are encoded by identical genes. The co­
receptor for CD4+ binds with HLA class II molecules whereas the co-receptor CD8+ 
binds with HLA class I molecules. If a macrophage with HLA of class I presents 
antigen to immature T-lymphocytes, it forms clones of cytotoxic T-lymphocytes. On the 
other hand, if a macrophage with HLA class II molecules presents the antigen, then it 
foims clones of helper T-lymphocytes. Each CD8+ T-lymphocyte destroys only a 
limited number of tumour cells after which the store of energy and perforins in these 
lymphocytes becomes depleted and the lymphocytes die out on their own (Walsh et al., 
2002).
Helper T-lymphocytes (CD4+) can be viewed as the main regulator by secreting 
cytokines; CD4+ lymphocytes influence the function of virtually all other cells of the 
immune system, including other T-lymphocytes, B-lymphocytes, macrophages, and 
natural killer cells. However, CD4+ lymphocytes are divided into two functionally 
distinct populations which have been recognised on the basis of the different cytokines 
they produce (Abbas et al, 1996). The T-helper type I (Thl) subset synthesises and 
secretes IL-2 and interferon-y (IFN-y) but not IL-4 or IL-5, whereas T-helper type II 
(Th2) produces IL-4, IL-5 and IL-13 but not IL-2 or IFN-y (Kidd, 2003).
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Lymphocytic infiltrations in tumour have been reliably demonstrated in a variety 
of solid tumours, including bladder cancer (Tanaka et a l, 1970, Stavropoulos et a l, 
1998, Bevers et a l, 2004) and suggest the presence of a local immuno-surveillance 
active immune defence of the host against bladder tumour (Tsujihashi et a l, 1989). In 
addition, bladder tumours with marked lymphocytic infiltration have a better response 
to BCG (Alexandroff, 1999). It was Tanaka and co-workers in 1970 who noticed that 
there is a significant lymphocytic infiltration to the bladder tumour; they reviewed 1090 
specimens of bladder tissue taken from 762 patients. They showed that lymphocytic 
infiltration is significantly more frequently associated with bladder cancer than benign 
lesions. Another interesting finding is that there was no correlation between infected 
urine proven on urine culture and lymphocytic infiltration (Tanaka et a l, 1970). The 
study did not however show a coiTelation between tumour lymphocytic infiltration and 
tumour aggressiveness, but this may have been due to the relatively short follow-up of 3 
years.
Natural Killer Cells (NK cells):
NK cells are natural, non-specific tumour killers and they play an important 
element in the anti-cancer system. The unique feature of NK cells is that they can 
destroy the cells in which there are low HLA class I molecule expressions. The major 
function of NK cells in fighting cancer is likely to be in surveillance and elimination of 
cells that become malignant before they can cause a tumour (Orange, Balias, 2006). 
After the close contact of NK cells with cancer cells, the NK cell seeretes perforins 
which lay out on the cancer cell surfaces to form pores and through which fluid will 
start to enter the cell through. The cancer cell slowly swells and at the end bursts. On 
the NK cell surfaces there are many stimulating molecules or activators. They are the
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receptors for IFN, IL-2, IL-12, IL-15, IL-18 molecules. On the surface of all the NK 
cells can be found the so called the Fas-ligand molecules (CD 178), which can trigger a 
cell death programme in the targeted eells. The activation of NK cells by interleukin 2 
and interleukin 12 leads to an intensive expression of CD 178 in NK cells. NK cells 
secrete gamma interferon which will stimulate T-helper 1 cells and Inhibit T-helper 2 
cells. A molecule important in down-regulating NK cell activity is prostaglandin Ei, 
which can be secreted by macrophages and tumour cells (Walsh et ah, 2002, Naim and 
Helbeit, 2002).
Macrophages
Macrophages are non-specific tumour killer cells which play a major element in 
the tumour surveillance role by differentiating normal from neoplastic cells. 
Macrophages are thought to be involved in four recognised functions that affect tumour 
immunity: phagocytosis, modulation of immunologic activation of lymphocytes, 
suppression of the immune response and direct destruction of tumour cells. Once the 
maerophages are activated, they increase phagocytosis, increase secretion of hydrolytic 
enzymes, release prostaglandin E, regulate ganulocyte/macrophage stem cell growth 
and suppress cellular proliferation. Macrophages present all types of antigens to T- 
lyiuphocytes in association with MHC class II molecules (Lewis and Pollard, 2006).
Compelling evidence has emerged in recent years that the macrophage plays an 
important role in tumour invasion, proliferation, angiogeuesis, immunosuppression and 
metastasis (Lewis and Pollard, 2006). Macrophage concentration and functional state at 
the tumour site affect the anti-tumour activity. Phenotypes of macrophage that infiltrate 
a tumour are called tumour-associated macrophages (TAM). TAMs are derived from 
circulating monocytic precursors, and are directed into the tumour by chemo-attractant
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cytokines such as colony-stimulating factor and chemokines. It is believed that the anti­
tumour activity is due to the ability to secrete vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), epidermal growth factor, tumour necrosis 
factor alpha (TNF alpha) and IL-8 (Lewis and Pollard, 2006). High TAM numbers 
have been shown to be an independent prognostic factor in many tumours including 
bladder cancer (Hanada et al., 2000, B ingle et al., 2002). Hanada and co-workers 
examined the relation between TAM, mi cro vessel density and clinical outcome in 63 
bladder cancer patients with a mean follow-up of 65 months. They found that TAM was 
higher in invasive bladder cancer and have a significant correlation with microvessel 
density. In addition, they found on multivariate analysis TAM and MCV were 
independent prognostic parameters (Hanada et al., 2000).
Dendritic cells
Dendritic cells are leucocytes that are highly specialised in the capture and 
presentation of antigens to T-lymphocytes. They can process the antigens, become 
activated, mature and migrate into lymphoid tissue, where they present antigen to 
lymphocytes to produce a specific immune reaction. Dendritic cells differ from 
macrophage and monocyte antigen-presenting cells because they are potent initiators of 
primary naive T-lymphocyte responses. They are believed to control the induction (and, 
possibly, the suppression) of antigen-specific immune responses (Nencioni and 
Brossart, 2004).
Injection of dendritic cells loaded with tumour-associated antigens into patients 
was shown to break tolerance and to induce anti-tumour cytotoxic immune responses. 
The dendritic cells- based clinical trials perfonned so far have demonstrated that this 
form of immunotherapy is feasible and safe (Banchereau et al., 2001).
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In summary, T-Iymphocytes can destroy tumour cells directly by apoptosis or 
perforin-mediated killing and indirectly by macrophages. NIC cells are involved in 
immune surveillance and mediate tumour cell killing by the lytic protein perforin. 
Macrophages are principal elements in immune surveillance. They release molecules 
that kill or inhibit tumour cells. B cells are indirectly involved in tumour cell killing 
through the formation of the antigen-antibody complex. Both cell-mediated and 
humoral immunity have been demonstrated to have anti-tumour activity.
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1.8.3. Cytokines
Cytokines are soluble protein substances produced by a wide variety of cell 
types and are critical to the functioning of both innate and adaptive immune responses. 
Cytokines have been variously named as lymphokines, interleukins and chemokines, 
based on their presumed function, and their cell of secretion or target of action.
Cytokines can be divided into two groups according to their function in relation 
to inflammation: promoting inflammation and are called pro-inflammatory cytokines; 
whereas other cytokines suppress inflammation and are called anti-inflammatory 
cytokines (Cytokines Web, 2006). However, there is no clear division between the two, 
e.g. IL-4, IL-10, and IL-13 are potent activators ofB lymphocytes. On the other hand, 
IL-4, IL-10, and IL-13 are also potent anti-inflammatory agents. Another classification 
divides cytokines into those that promote the proliferation and functioning of helper T- 
cells type 1 (IL-1, IL-2, IL-3, IL-12 and INF-y) and helper T-cells type 2 (IL-4, IL-5, 
IL-6, IL-10, IL-13 and TGF-p) (Figure 1.5).
In bladder cancer, high T-helper-type 1 (Thl) cytokines (INF y, IL-12 and IL-2), 
after BCG treatment has been observed to be a common feature in BCG responders. In 
contrast, higher levels of Th2 cytokines IL-10 and/or IL-6 appear to be associated with 
BCG failure (O'Donnell et al., 1996).
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Figure 1.5 The production o f cytokines.
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Interleukin-1 (IL-1) takes part in nearly all the phases of an immune response. 
IL-1 appears to activate cytotoxic T-lymphocytes and NK cells and takes part in the 
regulation of IL-2, lL-4, IL-6, IL-8 and granulocyte-macrophage colony-stimulating 
factor (GM-CSF). The active inhibitors of IL-1 production are IL-4, IL-10, IL-12 and 
the tumour necrosis factor -alpha (Kornman, 2006).
There are two types of this interleukin; IL-1 a and IL-lp which differ from each 
other in their bioactivities. IL-1 a, for example, appears to strengthen the weakening 
anti-tumour immunity, slows down tumour growth and lowers its metastatic potential. 
IL-lj3, on the other hand, appears to reinforce the regeneration of tissue and stimulates 
the metastatic processes (Komman, 2006).
For example, Seddighzadeh and co-workers (2003) reported that in 167 bladder 
tumours with a median follow-up of 56 months, low levels of IL-1 a expression were 
associated with an increased risk for cancer-specific death.
Interleukin-2 also appears to increase the function of T-cytotoxic lymphocytes 
and NK cells, promotes the production of perforins and IFN by these cells, activates the 
monocytes and macrophages which help to synthesise and secrete TNF, lL-1, IL-6, IL- 
8, and gi*anulocyte-colony stimulating factor (G-CSF). The function of IL-2 is 
dependent on its receptors IL-2 (IL-2R) (Nelson, 2004). It has been shown that the 
inhibition of IL-2 is associated with the accumulation of the immuno-suppressive 
substances, mainly the prostaglandins, immune complexes and the metabolic products 
of cancer cells developing an immunosuppression state (Nelson, 2004).
Interleukin-6 plays an important role in the anti-tumour activity in a number of 
ways. It is a pro-inflammatory cytokine; it modulates the anti-tumour activities of 
macrophages and stimulates the production of C-reactive protein. Interleukin-6 
regulates the immune system via the proliferation and activation of cytotoxic T cells.
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proliferation and differentiation of B cells, and production of acute phase proteins. In 
addition, IL-6 has been shown to regulate cell growth, differentiation and survival in 
other target cells (Horn et al., 2000).
Increased local IL-6 expression has been demonstrated in various cancers 
including bladder cancer. In addition, IL-6 takes part in pathogenesis of anorexia, 
cachexia and anaemia in cancer patients (Andrews et al., 2002). By blocking the genes 
or introducing the antibodies against IL-6, these clinical complications of cancer e.g. 
anorexia, cachexia and anaemia, reduce to milder fonns. Andrews and co workers 
found that plasma IL-6 levels were higher in patients with bladder cancer than in 
healthy controls. Levels of IL-6 and IL-6sR were associated with cancer stage and 
métastasés, and were strong independent predictors of disease recun ence and disease- 
specific suiwival (Andrews et al., 2002).
Interleukin-10 produced by T-lymphocytes, monocytes and macrophages, has a 
wide range of anti-inflammatory effects. The anti-inflammatory effect of IL-10 is 
expressed in terms of its ability to lower the production of pro-inflammatory cytokines, 
increase the production of IL-1 antagonist receptors and decrease the adhesion of 
leucocytes onto endothelial cells activated by IL-1. An elevated IL-10 level is 
associated with a raised IL-12 production and a reduction in IFN production (Mocellin 
et al., 2005). A high concentration of IL-10 is also a bad prognostic sign and generally 
corresponds with a rapid tumour growth and favours tumour escape from immune 
surveillance. However, a wealth of evidence is accumulating that IL-10 also possesses 
some immuno-stimulating properties. In fact, IL-10 has the combined ability of 
influencing positively and negatively the function of innate and adaptive immunity 
(Mocellin et al., 2005).
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Interleukin-12 is an activator of cellular immunity with anti-tumour and anti­
metastatic activities. IL-12 activates the cytotoxicity of macrophages; whereas the 
deficiency of its production by macrophages can significantly reduce the anti-tumour 
activities. IL-12 suppresses the development of cachexia and anaemia induced by IL-1 
and IL-6 in cancer patients. IL-12 stimulates the differentiation of T-lymphocytes to a 
T-helper 1 phenotype which in turn produce high amounts of IFN-y and cytotoxic cells. 
These biological properties seem useful in immune therapy for bladder cancer (Clinton 
et al., 2000).
Tumour Necrosis Factor TNF (cachexin) is an important cytokine involved in 
systemic inflammation and the acute phase response. TNF is released by leucocyte, 
endothelium and several other tissues in the course of damage. Its release is stimulated 
by several other mediators, such as IL-1. Some pre-clinical findings suggest that TNF 
may promote cancer development and progression, which has led to the proposition of 
anti-TNF therapy as a novel approach to malignancies (Mocellin et al., 2005). TNF has 
a number of actions on various organ systems generally, together with IL-1 and 11-6:
• On the hypothalamus; stimulating of the hypothalamic-pituitary-adrenal 
axis by stimulating the release of corticotrophin-releasing honnone (CRH), suppressing 
appetite (hence its name "cachexin") and fever.
• On the liver: stimulating the acute phase response, leading to an increase 
in C-reactive protein and a number of other mediators.
• It attracts neutrophils very potently, and helps them to stick to the 
endothelial cells for migration.
• On macrophages: stimulating phagocytosis, and production of IL-1 and 
prostaglandin E2.
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Interferons INF are natural proteins produced by the cells of the immune 
systems and are divided into interferon-alpha, beta and gamma. Interferon-alpha and 
beta are produced by many cell types, including T-lymphocyte and B-lymphocyte, 
macrophages, fibroblasts, endothelial cells, osteoblasts and others. They stimulate both 
macrophages and NK cells. Interferon-gamma has anti-viral and anti-tumour effects; 
stimulates macrophages and recmits leucocytes, resulting in increased inflammation. 
Interferon-gamma strengthens the effects of interferon-alpha and interferon-beta 
(Gattinoni et al., 2006)
Granulocyte Colony-Stimulating Factor G-CSF stimulates the survival, 
proliferation, differentiation, and function of neutrophils, gi anulocyte precursor cells 
and mature neutrophils. G-CSF is produced by endothelium, macrophages, and a 
number of other immune cells. The G-CSF-receptor is present on cells in the bone 
marrow and in response to stimulation by G-CSF, initiates proliferation and 
differentiation into mature granulocytes (Lopez-Lazaro, 2006).
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1.8.4 Acute-phase proteins
Acute-phase proteins are plasma proteins, mostly synthesised in the liver, and 
their plasma concentrations may increase several hundred-fold as part of the response to 
inflammatory stimuli. They promote inflammation, activate the complement cascade, 
and stimulate phagocytes (Du Clos, 2000). Three of the best-known examples of these 
proteins are C-reactive protein, fibrinogen, and serum amyloid A protein (figure 1.6). 
However, C-reactive protein is widely used because its measurement is standardised in 
the laboratory and available in hospitals. These proteins are synthesised in the liver by 
the hepatocytes and their synthesis is regulated by cytokines; especially IL-6, this 
synthesis is enhanced synergistically by IL-113 where IL-1 p enhances IL-6 induction 
through NF-kB (for C-reactive protein and fibrinogen) and IL-1 and TNF (for semm 
amyloid A) (Gabay and Kushner, 1999).
C-reactive protein was originally discovered by Tillett and Francis in 1930 as a 
substance in the serum of patients with acute inflammation that reacted with the C 
polysaccharide of pneumococcus. The C-reactive protein gene is located on the first 
chromosome. The function of C-reactive protein is believed to activate complement, 
binds to Fc receptors and acts as an opsonin for various pathogens. Interaction of C- 
reactive protein with Fc receptors leads to the generation of pro-inflammatory cytokines 
that enhance the inflammatory response (Du Clos, 2000). C-reactive protein recognises 
altered self and foreign molecules based on pattern recognition. Thus, C-reactive protein 
is thought to act as a suiweillance molecule for altered self and certain pathogens. This 
recognition provides early defence and leads to a pro-inflammatory signal and 
activation of the humoral, adaptive immune system (Marnell et al., 2005). High acute 
phase proteins were demonstrated in bladder cancer (Bastable et al., 1979, O'Quigley et 
al., 1981).
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Figure 1.6 Changing pattern of acute phase proteins after a moderate inflammatory 
stimulus (Adapted from Gabay and Kushner, 1999).
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In summary
Acute inflammation starts a cascade of cytokines and chemokines that attract 
immune and non-immune cells, mainly neutrophils, to infiltrate disrupted and damaged 
tissue. The process of acute inflammation is usually self-limiting because the production 
of pro-inflammatory cytokines gives way to anti-inflammatory cytokines as healing 
progresses. On the other hand, chronic inflammation is considered to be inflammation 
of prolonged duration in which active inflammation, tissue destruction, and attempts at 
repair are proceeding simultaneously. Although it may follow acute inflammation, 
chronic inflammation frequently begins insidiously, as low-grade, in this case, 
mononuclear cells, macrophages, lymphocytes, and plasma cells are found in addition 
to neutrophils, and active tissue destmction and repair proceed simultaneously (Figure 
1.7).
It has been hypothesised that the origin of many cancer is at sites of chronic 
inflammation (Virchow 1863). Although it is now clear that proliferation of cells alone 
does not cause cancer, sustained cell proliferation in an environment rich in 
inflammatory cells, growth factors, activated stroma, and DNA-damage-promoting 
agents, appears to promote neoplastic risk (Balkwill and Mantovani, 2001).
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2. HYPOTHESIS AND AIMS
The inter-relationship between tumour and host factors and disease progression 
in patients with transitional carcinoma of the urinary bladder is not clear. From the 
previous text, it would appear that the host inflammatory response plays an important 
role in the progression of bladder cancer. The presence of the tumour cells appears to 
activate the innate immune system as part of the host reaction to the presence of tumour. 
One scheme might be that the attraction and activation of various inflammatory cells at 
or near the tumour site leads to the release of various cytokines of which some will act 
locally on other inflammatory cells while others will find their way into the circulation 
and activate the systemic inflammatory response. The release of cytokines such as lL-6 
into the circulation will activate the release of the acute-phase proteins in the liver. The 
adaptive immune system will be activated due to the presence of antigens in the tumour. 
These tumour specific antigens will activate the humoral immune system and add to the 
inflammatory response. Therefore, rising acute phase proteins are usually a sign of 
disturbance of the host-tumour relationship.
The hypothesis of the present investigations is that there are significant local and 
systemic inflammatory responses and that these play a role in detennining cancer- 
specific survival of patients with transitional cell carcinoma of the urinary bladder.
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The aims of the thesis were to examine:
1. The prognostic value of the systemic inflammatory response in patients with 
transitional cell carcinoma of the urinary bladder.
2. The relationship between the systemic inflammatory response, tumour 
proliferative activity, T-lymphocytic infiltration, COX-2 expression, tumour 
associated macrophage and microvessel density and survival in patients with 
transitional cell carcinoma of the urinary bladder
3. The relationship between the systemic inflammatory response and the cytokines/ 
chemokines profile in patients with transitional cell carcinoma of the urinary 
bladder.
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CHAPTER 3: THE RELATIONSHIP BETWEEN THE SYSTEMIC 
INFLAMMATORY RESPONSE AND SURVIVAL IN PATIENTS WITH 
TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER. 
3.1 Introduction
Bladder cancer is the fourth most common malignancy in the United Kingdom 
in men and the eighth in women, with a total of 12,500 new cases each year causing 
5,000 deaths annually (CancerStats, 2002). More than 90% of bladder cancers 
diagnosed in the Western world are transitional cell carcinomas and constitute a 
significant proportion of the general urological consultant’s workload due to its high 
prevalence and recurrent nature.
It is increasingly recognised that, in addition to tumour stage, disease 
progression is dependent on a complex interaction of the tumour and host inflammatory 
response (Balkwill and Mantovani, 2001 ; Coussens and Werb, 2003). Indeed, the 
systemic inflammatory response, as evidenced by elevated circulating concentrations of 
C-reactive protein, has been shown to be a stage-independent prognostic factor in a 
variety of operable tumours (Mahmoud and Rivera, 2002; McMillan et al., 2003; Ikeda 
et al., 2003). To our knowledge there has been only one previous study which has 
examined the prognostic value of C-reactive protein in patients with invasive bladder 
cancer (O’Quigley et ah, 1981).
The aim of the present study was to examine the relationship between stage, 
grade, C-reactive protein and cancer-specific survival in patients with superficial or 
invasive bladder cancer.
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3.2 Patients and methods
Patients with biopsy-proven transitional cell carcinoma presenting to a single 
urological unit at Glasgow Royal Infirmary between 1992-1999 were reviewed. A 
cohort of 105 patients were selected on the basis of having a measurement of C-reactive 
protein prior to or 3-6 months following transurethral resection of bladder tumour. 
These were part of a larger cohort of 457 patients who underwent transurethral resection 
between 1992 and 1999 in Glasgow Royal Infinnary. The selected patients were 
similar in terms of age, sex, stage and grade compared with the original cohort (Table
3.1).
Those patients with a measurement of C-reactive protein prior to or 3-6 months 
following elective admission for transurethral resection of bladder tumour were 
included in the study as previously described (McMillan et al., 2003). Tumour stage 
was assessed using the UICC guidelines, and tumour grade performed according to the 
WHO grading system. Date and cause of death were obtained fiom clinical follow-up 
notes and corroborated with that from the Cancer Registry, Scotland using ICD codes 
(bladder cancer 1889).
Routine laboratory measurement of patients' serum for C-reactive protein 
concentration was perfonned. The limit of detection of the assay was a C-reactive 
protein concentration lower than 5 mg/1. The coefficient of variation, over the range of 
measurement, was less than 5% as established by routine quality control procedures. C- 
reactive protein measurement of greater than 10 mg/1 was considered to indicate the 
presence of systemic inflammatory response. (O’Gonnan et al., 2000).
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
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3.3 Statistical analysis
Sui'vival analysis was performed using the Cox proportional hazard model with 
patient age, sex, tumour stage and grade and C-reactive protein concentration as 
prognostic variables. Deaths up to September 2004 were included in the analysis.
Multivariate survival analysis was performed using stepwise backward 
procedure to derive a final model of the variables that had a significant independent 
relationship with survival. To remove a variable from the model, the corresponding P 
value had to be gi'eater than 0.10. Analysis was perfonned using SPSS software (SPSS, 
Chicago, Illinois, USA).
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II;
3.4 Results
The characteristics of patients with bladder cancer (n= 105) are shown in Table s
3.2). The majority were male, over the age of 65 years, had superficial disease (Ta, T l) IIand had elevated C-reactive protein concentrations either pre- or post-operatively.
Twenty four patients had adjuvant therapy (8 radiotherapy, 8 BCG, 8 cystectomy).
Thirty two patients had C-reactive protein concentrations determined both prior f
to and following the resection. Of the 20 patients with an elevated pre-operative value,
12 (60%) had a raised concentration after the operation. Of the 12 patients with a 
nonnal pre-operative value, 9 (75%) had a post-operative value in the normal range.
Raised C-reactive protein concentrations was associated with high tumour grade (Figure
3.1)
During the follow-up period 80 patients died, 41 of them from bladder cancer 
and the mean cancer specific sui'vival was 82.9 months (95% Confidence Interval 70.8- 
94.9). On univariate analysis, stage (p<0.001), gi'ade (p<0.01) and elevated C-reactive 
protein pre-operatively (p<0.05) and post-operatively (p<0.01) were significantly 
associated with overall survival. Also, stage (p<0.001), grade (p<0.001) and elevated 
C-reactive protein pre-operatively (p<0.05) and post-operatively (p<0.01) were 
significantly associated with cancer-specific survival (Table 3.3).
On multivariate analysis of patients who had a pre-operative C-reactive protein 
determination, stage (HR 4.00, 95%CI 2.02-7.94, p<0.001) and pre-operative C-reactive 
protein (HR 2.73, 95%CI 1.23-6.07, p=0.014) were independently associated with 
overall sui'vival. Also, stage (HR 3.37, 95%CI 1.37-8.29, p=0.008), gi'ade (HR 2.01,
95%CI 1.14-3.57, p=0.017) and pre-operative C-reactive protein (HR 3.31, 95%CI 
1.09-10.09, p=0.035) were independently associated with cancer-specific survival.
Those patients with an elevated pre-operative C-reactive protein concentration had a
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mean cancer-specific survival of 65.5 months (95%CI 46.8-84.2) compared with 103.7 
months (95%CI 81.8-125.6) in those patients with a C-reactive protein concentration in 
the nonnal range (Figure 3.2).
71
3.5 Discussion
In the present study, both tumour grade and the presence of a systemic 
inflammatory response, as evidenced by elevated circulating concentrations of C- 
reactive protein, were independent predictors of cancer-specific survival in patients with 
bladder cancer. These results confinn the importance of tumour grade as a stage- 
independent prognostic factor (Ali-El-Dein et al, 2003; Nishiyama et al, 2004) and are 
consistent with the work of O ’Quigley et al (1981), who reported that an elevated C- 
reactive protein concentration, measured by radial immunodiffusion and using the limit |
of sensitivity of 12mg/l as a cut-off, was associated with poor suiwival in patients with 
invasive bladder cancer.
Furtheiinore, because C-reactive protein concentration is independent of tumour 
stage and grade, the presence or absence of a systemic inflammatory response might 
form the basis of a new prognostic score that reflects not only the tumour but also the 
host response. Indeed, this approach has recently been used in both lung and colorectal 
cancer (Forrest et al., 2003; Canna et al., 2004).
There has been only one previous report on which to base a sample size.
O’Quigley and co-workers (1981) reported a significant relationship between elevated 
C-reactive protein concentrations and suiwival in 82 patients with invasive bladder 
cancer. The numbers of patients who died in the follow-up period was not stated. In 
the present study we had 105 patients, superficial and invasive disease, of whom 80 
(76%) patients died during the follow-up period. Therefore, it is likely that the results 
of the present study are reliable and are consistent with the only other previous 
published study.
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Although in the present study, it may appear horn the present results that an 
elevated post-operative C-reactive protein concentration is a better predictor of cancer- 
specific survival than an elevated concentration prior to resection, in a clinical context 
the measurement of pre-operative CRP concentration is likely to be of more value 
because it would allow plamiing of adjuvant therapy.
The mechanisms by which a systemic inflammatory response might impact on 
cancer-specific survival are not clear. However, it is known that as part of the systemic 
inflammatory response to the tumour there is a release of pro-inflammatory cytokines 
and growth factors which not only stimulate tumour growth (Abramovitch et al., 1999; 
Coussens and Werb, 2003) but also produce profound catabolic effects on host 
metabolism (Kotler, 2000). For example, interleukin-6, produced by the tumour or 
infiltrating inflammatory cells, is recognised as a growth promoter in bladder cancer 
(Okamoto et al., 1997; Andrews et 2002). Interleukin-6 also stimulates liver production 
of acute-phase proteins, such as C-reactive protein, which increases the demand for 
certain amino acids, which, if  limited in the diet, must be obtained from the breakdown 
of skeletal muscle (Preston et al., 1998; McMillan et al., 1998). In this way, the 
presence and magnitude of a chronic systemic inflammatory response may produce a 
progressive nutritional and functional decline, ultimately resulting in reduced suiwival.
In summary, it would appear that the systemic inflammatory response is a stage 
and grade-independent prognostic factor in patients with bladder cancer. The role of the 
systemic inflammatory response in detennining disease-specific survival in patients 
with bladder cancer is worthy of further study to establish its value as a prognostic 
factor.
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Table 3.1 Clinical characteristics for all patients with bladder cancer attended between 
(1992-1999) and the selected cohort.
Original cohort Selected
N=457 (100%) 11=105 (1
<65 yrs 146 (32) 37 (35)
>65 yi's 220(68) 68(65)
Male 329 (72) 75(71)
Female 128 (28) 30 (29)
Superficial (Ta, T l) 352 (77) 76(72)
Invasive 105 (23) 29(28)
: G1 169 (37) 36(34)
G2 151 (33) 31 (30)
G3 137 (30) 38 (36)
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Table 3.2 Clinical characteristics and sui-vival in patients with bladder cancer.
Patients
Age <65 yrs 
>65 yrs 
Sex: Male
Female 
Stage Superficial (Ta,T 1 ) 
Invasive 
Grade G1 
G2 
G3
Pre-operative
C-reactive protein < 10 mg/1 
>10 mg/1
Post-operative
C-reactive protein < 10 mg/1 
>10 mg/1
Adjuvant therapy 
No 
Yes 
Alive 
Dead
Bladder cancer-specific 
IntercuiTent
105 (100%) 
37 (35)
68 (65)
75 (71) 
30(29) 
76(72) 
29(28)
36 (34)
31 (30) 
38(36)
16(15)
43 (41)
36 (34) 
42(40)
81 (77) 
24(23)
25 (24)
41 (39)
39 (37)
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Table 3.3 The relationship between variables and overall and cancer-specific survival 
in patients with bladder cancer; univariate analysis
Overall Cancer-specific
Hazard Ratio P-value* Hazard Ratio P-value'^' 
Age (<65/>65yrs) 0.063 0.142
Sex (Male/ Female) 0.338 0.803
Stage
(Superficial/Invasive) 2.82 (1.74-4.57) <0.001 4.96(2.61-9.41) <0.001
Grade ( G l /0 2 /G3) 1.48 (1.14-1.92) 0.004 2.17 (1.45-3.23) <0.001
Pre-operative 
C-reactive protein
(<10/>10 mg/1) 2.50(1.15-5.43) 0.021 3.03 (1.04-8.87) 0.043
Post-operative
C-reactive protein
(<10/>10 mg/1) 2.31 (1.34-3.97) 0.003 3.28 (1.41-7.63) 0.006
Adjuvant therapy
(No/ Yes 0.537 0.732
Values in parentheses are 95% confidence intervals. *Cox proportional hazard model.
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Figure 3.1 The relationship between the variance in C-reactive protein concentrations 
and tumour grade in patients with transitional cell carcinoma of the urinary bladder.
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Figure 3.2 The relationship between high vs. normal C-reactive protein and survival 
in patients with transitional cell carcinoma of the urinary bladder.
78
CHAPTER 4: THE RELATIONSHIP BETWEEN THE SYSTEMIC 
INFLAMMATORY RESPONSE, TUMOUR PROLIFERATIVE ACTIVITY. T- 
LYMPHOCYTIC INFILTRATION. TUMOUR ASSOCIATED MACROPHAGE. 
MICROVESSEL DENSITY AND COX-2 EXPRESSION AND SURVIVAL IN 
PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY 
BLADDER.
4.1 Introduction
It is increasingly recognised that disease progression is dependent on a complex 
interaction of the tumour and the host inflammatory response (Balkwill and Mantovani, 
2001, Coussens and Werb, 2002, Vakkila and Lotze, 2004). Recently, the systemic 
inflammatory response, as evidenced by elevated circulating concentrations of C- 
reactive protein, has been shown to be independently associated with poorer survival in 
patients with advanced cancer (O’Goiman et al., 2000, Forrest el al., 2003, Maltoni et 
al., 2005). There is also evidence that C-reactive protein has independent prognostic 
value in primary operable cancer (McMillan et al., 2003, Ikeda et al, 2003, Jamieson et 
al., 2005, Lamb et al., 2006; Crumley et al., 2006). Therefore, it would appear that the 
systemic inflammatory response is of considerable importance in the relationship 
between the tumour, the host and outcome in patients with cancer. Recently, we have 
reported that an elevated C-reactive protein was associated with poor cancer-specific 
sui*vival in patients with bladder cancer independent of tumour stage and grade (Hilmy 
et al., 2005).
The basis of the independent relationship between an elevated C-reactive protein 
concentration and poor survival in cancer is not clear. There are a number of possible 
explanations. Firstly, that an elevated C-reactive protein identifies tumours capable of
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producing significant amounts of pro-inflammatory cytokines, either directly or 
indirectly, in particular interleukin-6 (Kinoshita et al., 1999, McKeown et al., 2004) and 
therefore with the potential for more rapid gi'owth of tumour cells (Jee et al., 2001, 
Trikha et al., 2003) or with impaired T-lymphocytic function (Maccio et al., 1998,
Canna et al., 2005) allowing unrestrained tumour gi’owth and dissemination.
Precise localisation of pro-inflammatory cytokines to tumour cells or 
inflammatory cells within the tumour, particularly in paraffin embedded tissues, 
remains problematical (Canna et al, 2005). However, tumour proliferative activity has 
been reliably assessed using the Ki-67 labelling index in a variety of solid tumours, 
including bladder cancer (Habuchi et al., 2005, Blanchet et al., 2001). Also, infiltration 
of tumours with T- lymphocytes and macrophages has been reliably demonstrated in a 
variety of solid tumours, including bladder cancer, and appears to have independent 
prognostic value (Bevers et al., 2004, Stavropoulos et al., 1998; Hanada et al., 2000, 
Bingle et al., 2002). In addition, macrophage tumour infiltration has been shown to be 
higher in invasive bladder cancer and have a significant association with microvessel 
density and suiwival (Hanada et al., 2000).
Central to the local inflammatory response is cyclooxygenase-2 and increased 
expression has been shown to be associated with poor suiwival in a number of common 
solid tumours (Dannenberg et al., 2001, Dannenberg and Subbaramaiah, 2003). The aim 
of the present study was therefore to examine the relationship between the systemic 
inflammatory response (C-reactive protein), tumour proliferative activity (Ki-67), 
tumour T-lymphocyte (CD4+, CD8+) infiltration, tumour macrophage (CD68) 
infiltration, tumour microvessel density (CD34), tumour COX-2 expression and cancer- 
specific suiwival in patients with transitional cell carcinoma of the bladder.
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4.2 Patients and Methods
A cross-sectional study of patients with biopsy-proven transitional cell 
carcinoma and with a measurement of C-reactive protein prior to transurethral resection 
of bladder tumour in Glasgow Royal Infirmary between 1992 and 2001 was carried out. 
Tumours were grouped according to whether they had superficial (pTa, pTl and CIS) or 
muscle-invasive (pT2-pT4) disease. However, patients with G3 pTl were considered as 
muscle-invasive tumours since they are recognised to have a significantly higher 
progression rate (Manoharan and Soloway, 2005). At this time no patient showed 
clinical evidence of infection, or other inflammatory conditions. Tumour stage was 
assessed using the 1997 AJCC/UICC TNM classification (Sobin and Witteking, 2002) 
and tumour grade performed according to the 1999 WHO grading system (Busch and 
Algaba, 2002).
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
C-reactive protein measurement
Routine laboratory measurement of patients' serum for C-reactive protein 
concentration was performed. The limit of deteetion of the assay was a C-reactive 
protein concentration lower than 5 mg/1. The coefficient of variation, over the range of 
measurement, was less than 5% as established by routine quality control procedures. C- 
reactive protein measurement of greater than 1 Omg/1 was considered to indicate the 
presence of systemic inflammatory response (O'Gorman et al., 2000).
Immunohistochemistrv
Blocks from the primary tumour were fixed in 10% buffered fonnalin and 
embedded in paraffin wax. One representative block of tumour was selected for each 
patient. Sections (4mm) were cut and mounted on slides coated with 
aminopropyltriethoxysilane and placed in oven at 56 °C for 40 minutes. Slides were 
dewaxed in xylene for 4 minutes twice and rehydrated through graded alcohols then 
rinsed with water.
The following monoclonal antibodies were used: Ki-67 (Dako, Cambridgeshire, 
UK) at 1:200 dilution, CD4 (Vector, Peterborough, UK) at 1:10, CD8 (Dako, 
Cambridgeshire, UK) at 1:200, COX-2 human IgG (Cayman Chemical CO., MI, USA) 
at 1:800, CD68 (Dako, Cambridgeshire, UK) at 1:200 and CD34 (Novocastra, 
Newcastle upon Tyne, UK) at 1:100.
Antigen retrieval for Ki-67, CD4, CDS, CD68, CD34 and COX -2 was carried 
out by microwaving in ImM Tris BDTA buffer (0.37g Sodium EDTA, 0.55g Tris in 1 
litre distilled water) for 5 minutes under full pressure in a plastic pressure cooker in a 
850W microwave on full power.
Staining method for Ki-67, CD4, CDS, CD34 and CD68 was as follows:
1. 5% Nonnal Goat Serum 20 minutes.
2. Primary antibody 30 minutes.
3. Wash in Tris Buffered Saline (TBS).
4. Hydrogen Peroxide blocking agent (Dako S2023)
5. Wash in TBS
6. Envision (Dako, Cambridgeshire, UK) 30 minutes
7. Wash in TBS
8. DAB (Dako, Cambridgeshire, UK) 10 minutes
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COX-2 sections were immunostained using the biotinylated/streptavidin 
peroxidase complex (Dako, Cambridgeshire, UK) technique. Sections were then 
incubated in 3’3’diaminobenzidine (DAB, Dako, Cambridgeshire, UK) as a substrate 
for 10 minutes at room temperature.
Negative controls were stained using antibody-diluting fluid alone. Finally, 
copper enhancement was carried out for 5 minutes. Then, tissues were counter-stained 
with haematoxylin for 1 minute then washed with water, followed by scotts water for 
another minute before washing them with water. Slides were dehydrated through 
graded alcohols 70%, 90% and 100%, two minutes each, and xylene for two five 
minutes. The slides were cleared, mounted with Pertex and appropriate slide covers 
applied.
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Morphometry
Ki-67
Quantitative analysis of the Ki-67 expression tumour cells was performed by 
identifying the Ki-67 labelling index. The percentages of Ki-67-reactive tumour cells 
were evaluated x 400 magnification by scoring a minimum of 1000 tumour cells in 
randomly selected fields (Figure 4.1). Only fields containing tumour tissues were 
counted. Any normal tissue on the slide was excluded h'om the analysis.
CD4+ and CD8+
Quantitative analysis of the lymphoid infiltrate was perfonned using point 
counting (Anderson et al., 1965) with a random sampling technique. With this method, 
the volume occupied by any given component - volume density (Vy) - is expressed as a
percentage of the total volume of the tissue. The volumes of CD4 and CDS (Figure 4.2 
and 4.3) immunopositive cells were calculated as percentage of the total tumour 
volume. A 100 point ocular grid was used at x 400 magnification and 30 fields were 
counted per case for each antibody. Only fields containing tumour tissues were 
counted. Any normal tissue on the slide was excluded from the analysis.
The volume density (Vy) of CD4 and CD8-positive lymphocytes was calculated
for each tumour including tumour nest and stroma.
CD 68 and CD 34
Quantitative analysis of the tumour associated macrophage (Figure 4.4) / 
microvessel density (Figure 4.5) was by selecting three areas with high density of 
macrophages/neovascularisation (hot spots), where the highest numbers of 
macrophage/discrete vessels were stained at low power (4 x 10). Counting of
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macrophage/discrete vessels was performed using a magnification of x200 (x20 
objective and 1x10 ocular piece) using an ocular grid (10 x 10 square/ 0.25mm^). Only 
fields within the tumour (including cancer cell nests and surrounding tissue stroma) 
were counted. Any normal tissue on the slide was excluded from the analysis.
COX-2
Semi-quantitative analysis of the COX-2 expression was scored using a 
weighted histoscore method. Histoscores were calculated fiom the sum of (1 x %  cells 
staining weakly p o s i t iv e ) + (2 x %  cell staining moderately p o s i t iv e ) + (3 x %  cells staining 
strongly positive) with a maximum of 300. Examples of positive staining patterns for 
cyclo-oxygenase-2 are shown Figure 4.6a, 4.6b and 4.6c.
All cases were counted by the author. For the purpose of assessing inter­
observer reproducibility, a second obseiwer (RC, AA) independently scored the slides. 
The agreement between observers was excellent (intra-class correlation coefficient 
(ICCC) (> 0.900) with no systematic differences. The observers were blinded to the 
clinical outcome of the patient.
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Figure 4.1 Immunohistochemical staining of Ki-67 antigen (brown) in transitional 
cell carcinoma of the urinary bladder
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Figure 4.2 Immunohistochemical staining of CD4+ antigen (brown) in transitional 
cell carcinoma of the urinary bladder
87
:  f  ^
4 '  '
*  *  ^  *  f  '  ^ - 4 . . ,^ Q . \  -
S «
Figure 4.3 Immunohistochemical staining of CD8+ antigen (brown) in transitional 
cell carcinoma of the urinary bladder
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Figure 4.4 Immunohistochemical staining of CD 68+ antigen in transitional cell 
carcinoma of the urinary bladder
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Figure 4.5 Immunohistochemical staining of CD 34+ antigen in transitional cell 
carcinoma of the urinary bladder
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Figure 4.6 a Immunohistochemical staining of COX-2 antigen (brown) in 
transitional cell carcinoma of the urinary bladder — strong expression
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Figure 4.6 b Immunohistochemical staining of COX-2 antigen (brown) in transitional 
cell carcinoma of the urinary bladder -  moderate expression
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Figure 4.6 c Immunohistochemical staining of COX-2 antigen (brown) in transitional 
cell carcinoma of the urinary bladder -  mild expression
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4.3 Statistical Analysis
Data are presented as median and range. For the purpose of analysis the tumour 
Ki-67 labelling index, CD4+ and CD8+ T-lymphocyte counts, CD68+ and CD34+ and 
COX-2 expression were grouped by fertiles. The relationships between these and other 
variables were analysed using the Mantel-Haenszel (X^) test for trend and Speannan 
rank correlation as appropriate.
Survival analysis was performed using the Cox proportional hazard model.
Multivariate survival analysis was performed using stepwise backward procedure to 
derive a final model of the variables that had a significant independent relationship with 
survival. To remove a variable from the model, the corresponding P-value had to be a 
greater than 0.10. Analysis was performed using SPSS software (SPSS Inc., Chicago, 
IL, USA).
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4.4 Results
The characteristics of patients with bladder cancer (n= 103) according to stage 
are shown in the Table 4.1. The majority of patients were male, over the age of 65 
years, had superficial disease and had elevated C-reactive protein concentration pre- 
operatively. Patients with invasive bladder cancer were older (p<0.01), had higher 
grade tumours (p<0.001), elevated C-reactive protein concentrations (p<0.05) and an 
increased Ki-67 labelling index (p<0.001) compared with superficial disease. Also, 
patients with invasive disease had greater tumour infiltration of CD4+ (p<0.05) and 
CD8+ T-lymphocytes (p<0.01) and macrophages (p<0.001). Compared with superficial 
disease, patients with invasive bladder cancer had increased tumour microvessel density 
(p<0.001) and increased tumour expression of COX-2 (p<0,001). Patients with invasive 
bladder cancer received more adjuvant therapy (p<0.05). In total, 22 patients had 
adjuvant therapy (7 cystectomy, 9 radiotherapy and 6 BCG). Cancer-specific survival 
was shorter in those patients with invasive compared with superficial bladder cancer
(p<0.001).
The minimum follow-up was 47 months; the median follow-up of the survivors 
was 60 months. Duiing the course of the study, 66 patients died; 42 patients of their 
cancer and 24 of intercurrent disease. On univariate analysis, stratified by stage, 
elevated C-reactive protein (p<0.05), increased Ki-67 labelling index (p<0.05), 
increased tumour macrophage infiltration (p<0.01), increased tumour micro vessel 
density (p<0.001), increased COX-2 expression (p<0.05) and adjuvant therapy (p<0.01) 
were associated with poorer cancer-specific survival (Table 4.2).
On multivai'iate analysis of these significant factors, stratified by stage, only 
elevated C-reactive protein (HR 2.47, 95%CI 1.18-5.18, p=0.017), increased tumoui’ 
macrophage infiltration (HR 2.77, 95%CI 1.52-5.04, p<0.001) and adjuvant therapy
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(HR 0.25, 95%CI (0.11-0.56, p<0.001) were independently associated with poorer 
cancer-specific survival. When C-reactive protein was excluded from the multivariate 
analysis, stratified by stage, only increased tumour macrophage infiltration (HR 2.71, 
95%CI 1.50-4,91, p<0.001), increased tumour micro-vessel density (HR 1.63, 95%CI 
(1.00-2.64, p=0.049) and adjuvant therapy (HR 0.33, 95%CI (0.15-0.69, p=0.004) were 
independently associated with poorer cancer-specific survival.
The inter-relationships between the clinicopathological characteristics are shown 
in Table 4.3 and Figures 4.7a, 4 .7b and 4.7c. In all patients, tumour grade was directly 
associated with Ki-67 labelling index (p<0.001), CD4+ (p<0.01) and CD8+ (p<0.001) 
T-lymphocytes, CD68+ (p<0.001), CD34+ (p<0.01) and COX-2 expression (p<0,001), 
but not with C-reactive protein (p=0.152). An elevated C-reactive protein concentration 
was directly associated with the Ki-67 labelling index (p<0.05), CD68+ (p<0.001) and 
CD34+ (p<0.01). The Ki-67 labelling index was directly associated with CD4+ 
(p<0.001) and CD8+ (p<0.01) T-lymphocytes and CD68+ (p<0.001), CD34+ (p<0.001) 
and COX-2 expression (p<0.001). The tumour CD4+ T-lymphocytic infiltrate was 
directly associated with CD8+ (p<0.001), CD68+ (p<0.05), and COX-2 expression 
(p<0.01). The tumoui' CD8+ T-lymphocytic infiltrate was directly associated with 
COX-2 expression (p<0.05). The tumour CD68+ macrophage infiltrate was directly 
associated with CD34+ microvessel density (p<0.001) and COX-2 expression 
(p<0.001). The tumour CD34+ microvessel density was directly associated with COX- 
2 expression (p<0.001).
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4.5 Discussion
In the present study, tumour grade and Ki-67 labelling index were closely 
associated with tumour T-lymphocytic and macrophage infiltrate, microvessel density 
and COX-2 expression. However, on multivariate analysis, when stratified for tumour 
stage, Ki-67 labelling index, macrophage infiltration and microvessel density but not T- 
lymphocytic infiltration or COX-2 expression were independently associated with 
cancer-specific survival Furthermore, of these significant factors, tumour macrophage 
infiltration was the strongest. Taken together, the results of the present study would 
suggest that tumour macrophage infiltration is an important host response associated 
with disease progression and poor survival in patients with transitional cell cai’cinoma 
of the urinary bladder.
It was of interest that tumoui* macrophage infiltration was also associated with 
an elevated C-reactive protein concentration which was also independently associated 
with poorer cancer-specific survival. This relationship may reflect increased 
production, by macrophages, of interleukin-6 which is closely associated with liver 
production of C-reactive protein, a sensitive marker of the systemic inflammatory 
response (Gabay and Kushner, 1999). Taken together these observations would suggest 
that macrophage production, rather than tumour production, of interleukin-6 drives the 
systemic inflammatory response seen in bladder cancer.
These results aie consistent with the report that an increase in interleukin-6 and 
its soluble receptor are associated with advanced tumour stage and predict disease 
recurrence and cancer-specific survival (Andrews et a l, 2002). It remains to be 
determined whether the measurement of circulating interleukin-6 concentration offers 
superior prognostic value to that of either tumour macrophage infiltration or circulating 
C-reactive protein in patients with bladder cancer.
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It was of interest that the tumour Ki-67 labelling index was associated with 
increased tumour infiltration by CD4+ and CD8+ T-lymphocytes in both superficial and 
invasive disease. These results are consistent with the concept that there is an active 
immune response to tumour cell proliferation in patients with transitional cell carcinoma 
of the urinary bladder and that bladder cancer is one of the few solid cancers to be 
treated successfully with immunotherapy. Indeed, intravesical treatment of superficial 
carcinoma with bacillus of Calmette and Guerin (BCG) vaccine reduces both disease 
recurrence and progression (Lamm et al., 2000). Furthermore, studies have shown that 
patients with marked lymphocytic infiltration have a better response to BCG 
(Alexandroff et al., 1999).
In summary, the results o f the present study shows that, in addition to grade and 
Ki-67 labelling index, both local (CD68+ macrophages) and systemic (C-reactive 
protein) markers of the inflammatory response were associated with poor cancer- 
specific survival.
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Table 4.1 The relationship between tumour stage and clinicopathological characteristics
in patients with bladder cancer.
Superficial
(n=61)
Invasive 
(n= 42)
P-value
Age group (<65/ >65) 30/31 10/ 32 0.010
Sex (male/ female) 44/17 26/16 0.277
Tumour grade
G l/ G2/ G3 26/ 32/ 3 0/ 6/ 36 <0.001
C-reactive protein
(<10/ >10mg/l) 32/29 13/ 29 0.031
% Tumour volume
Ki-67 (fertiles 1 ,2 ,3 ) 30/ 20/ 11 5/14/23 <0.001
T-lymphocytes
CD4+ (fertiles 1 ,2 ,3 ) 25/21/15 10/13/19 0.022
CD 8+ (fertiles 1 ,2 ,3 ) 26/21/ 14 9/13/ 20 0.005
CD68+ (tertiles 1 ,2 ,3 ) 3 4 /2 1 /6 0 /1 3 /2 9 <0.001
CD34+(fertiles 1,2, 3) 2 9 /2 0 /1 2 5 /1 4 /2 3 <0.001
COX-2 (tertiles 1 ,2 ,3 ) 30/ 26/ 5 4/ 9/ 29 <0.001
Adjuvant therapy (no/ yes) 53/8 28/ 14 0.014
Cancer-specific survival
(months) 109 (94-125)* 41 (24-58)* <0.001
*Mean (95%CI)
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Table 4.2 The relationship between clinicopathological chai*acteristics and cancer- 
specific survival, stratified by stage, in patients with bladder cancer; univariate survival 
analysis.
Patients Hazard ratio P-value
(n= 103) (95%CI)
Age group (<65/ >65) 40/ 63 1.52 (0.76-3.02) 0.234
Sex (male/ female) 70/33 0.72 (0.37-1.39) 0 J22
Tumour grade
G l/ G2/ G3 26/38/39 1.18(0.57-2.48) 0.653
C-reactive protein
(<10/>10mg/l) 45/58 2.36(1.17-4.74) 0.016
% Tumour volume
Ki-67 (tertiles 1 ,2 ,3 ) 34 (2-80)* 1.73 (1.11-2.72) 0.017
T-lymphocytes
CD4+ (tertiles 1 ,2 ,3 ) 2.70 (0-12.30)* 1.26 (0.84-1.88) 0.260
CD8+ (tertiles 1 ,2 ,3 ) 2.20 (0.16-10.20)* 1.27 (0.87-1.86) 0.221
CD68+ (tertiles 1 ,2 ,3 ) 55 (18-98)* 2.48 (1.40-4.42) 0.002
CD34+ (tertiles 1 ,2 ,3 ) 49 (20-98)* 2.13 (1.27-3.57) 0.004
COX-2 (tertiles 1 ,2 ,3 ) 200 (100-300)* 1.93 (1.10-3.39) 0.023
Adjuvant therapy
(no/ yes) 81/22 0.36 (0.17-1.75) 0.006
* median (range).
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Figure 4.7a The relationship between CD68+ (tumour associated macrophage, TAM) and 
COX-2 expression (p <0.001) in patients with transitional cell carcinoma of the urinary 
bladder.
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Figure 4 .7b The relationship between CD68+ (tumour associated macrophage, TAM) and 
Ki-67 proliferative index (p <0.001) in patients with transitional cell carcinoma of the 
urinary bladder.
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CD34+ expression (microvessel density), (p <0.001) in patients with transitional cell 
carcinoma of the urinary bladder.
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CHAPTER 5: THE RELATIONSHIP BETWEEN THE SYSTEMIC 
INFLAMMATORY RESPONSE AND CYTOKINES/ CHEMOKINES PROFILE IN 
PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY 
BLADDER.
5.1 Introduction:
It is increasingly recognised that, in addition to tumour stage and proliferative 
activity, disease progr ession is dependent on a complex interaction of the tumour and host 
inflammatory response (Balkwill and Mantovani, 2001; Coussens and Werb, 2002), 
Indeed, in chapter 3 we have shown that, in addition to stage and gr ade, the systemic 
inflammatory response, as evidenced by elevated circulating concentrations of C-reactive 
protein, was associated with poor cancer-specific survival.
It is now recognised that elevated circulating concentrations of C-reactive protein 
reflect the net effect of hormones and cytokines/chemokines (Gabay and Kushner, 1999). 
To date, few studies have examined the cytokines/chemokines profile associated with an 
elevated C-reactive protein concentration in patients with cancer. Such profiles may be 
useful in identifying which immime cells are activated and play a role in the elaboration of 
C-reactive protein. The aim of the present study was to examine the relationship between 
circulating concentrations of C-reactive protein and cytokines produced by T-lymphocyte 
subset populations in patients with transitional cell carcinoma of the bladder.
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5.2 Methods:
A prospective study of newly diagnosed patients with transitional cell carcinoma of 
the bladder at hospitals in the North Glasgow Trust was studied. Prior to elective 
admission for transurethral resection of the bladder tumour, blood samples were taken for 
routine laboratory measurement of C-reactive protein measurement and plasma storage for 
cytokines/ chemokines profile measurement.
Inclusion criteria were newly-diagnosed patients with transitional cell carcinoma of 
the bladder and signed informed consent. Exclusion criteria were patients with a known 
systemic inflammatory condition e.g. inflammatory bowel disease, rheumatoid arthritis or 
known infection at the time of entry into the study. Following discussion of the study with 
the patient and completion of the consent form, two 4ml blood samples were taken prior to 
the transurethral resection of the bladder tumour. The samples were centrifuged and the 
plasma is frozen and stored at -20 degrees.
Tumours were divided into two groups, superficial (pTa, pTl and CIS) and muscle 
invasive (pT2-pT4). However, patients with pTl G3 were grouped with the muscle- 
invasive tumours since such tumour have a significant higher progression rate (Manoharan 
and Soloway, 2005). At this time no patient showed clinical evidence of infection, or other 
inflammatory conditions. Tumour stage was assessed using the 1997 AJCC/UICC TNM 
classification (Sobin and Witteking, 2002) and tumour gi'ade performed according to the 
1999 WHO grading system (Busch and Algaba, 2002). The Research Ethics Committee of 
North Glasgow NHS Trust approved the study.
The limit of detection of the assay for C-reactive protein was 5 mg/1. The 
coefficient of variation, over the range of measurement, was less than 5% as established by
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routine quality control procedures. C-reactive protein measurement of greater than 1 Omg/1 
was considered to indicate the presence of systemic inflammatory response (O’Gorman et 
al., 2000).
Frozen plasma samples stored at -20°C were thawed once and 50 ql was used to 
measure cytokine levels utilising the novel Luminex technology, a development on 
multiplex assays first described in 1977 (Horan and Wheeless, 1977). Luminex technology 
utilises patented pre-dyed microspheres allowing up to 100 analytes to be measured 
simultaneously in the one biological sample. Briefly, an individual bead set is coated with a 
capture antibody against the analyte (cytokine) of choice. Combinations of these bead sets 
are then incubated with sample and thereafter a cocktail o f detection antibodies labelled 
with a reporter flourochrome is added similar to a conventional sandwich ELISA. Detection 
of beads and quantification of analytes was perfoimed using a Multiplex system and Bio- 
Plex software (Bio-Rad, California, USA).
In the present study the analysis was canied out as per manufactui*er’s instiuction 
using preconftgui’ed multiplex cytokine kits (Biosoui'ce, California, USA).
From examination of the cytokine data and the report of de Jager and co-workers 
(2003) it was clear that the sensitivity was limited to 5pg/ml in this assay system and 
therefore cytokines/chemokines concentrations measured below this limit were set to 
5pg/ml.
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5.3 Statistical Analysis
Data are presented as median and range. Inflammatory cytokines/chemokines 
profile concentration below the thieshold of sensitivity of the respective assays were 
expressed as equal to this threshold. Where appropriate, data were tested for statistical 
significance using the Mann-Whitney U test. Analysis was performed using SPSS software 
(SPSS Inc., Chicago, IL, USA).
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5.4 Results:
The characteristics of patients with bladder cancer (n= 47), grouped according to the 
presence and absence of a systemic inflammatory response, ai-e shown in Table 1. The 
majority of patients were male, over the age of 65 years, had superficial disease and a C- 
reactive protein concentration in the normal range. In total, 16 patients had adjuvant 
therapy (7 cystectomy, 2 radiotherapy and 7 BCG).
Of the ThO type cytokines/chemokines measured, IL-6, IL-7, IL-8, IL-15 and GM- 
CSF had median concentrations below the limit of detection (5pg/ml) irrespective of their 
C-reactive protein concentrations, tumour stage and grade. IL-lb, and IL-12 had similar 
detectable concentrations irrespective of their C-reactive protein concentrations, tumour 
stage and grade.
Of the Thl type cytokines/chemokines measured, IL-2, interferon-gamma and TNF- 
alpha had median concentrations below the limit of detection (5pg/ml) irrespective of their 
C-reactive protein concentrations, tumour stage and grade.
Of the Th2 type cytokines/chemokines measui ed, IL-4, IL-5, IL-10 and IL-13 had 
median concentrations below the limit of detection (5pg/ml) irrespective of their C-reactive 
protein concentrations, tumour stage and grade.
Of the macrophage/monocyte-type cytokines/chemokines (MIP-1 alpha, MIP-1 beta 
and MCP-1) and eosinophils-type cytokines/chemokines (EOTAXIN) had detectable 
median plasma concentrations but also were not associated with elevated C-reactive protein 
concentrations, tumour stage and grade apait h'om MIP-1 beta which was associated with 
tumour stage (p=0.043). These findings were inconclusive because of the low 
concentrations measured in the plasma.
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5.5 Discussion
It is well recognised that cytokines are secreted by and are regulators of immune 
system. Furthermore, different cytokine functions are complex and overlapping and 
therefore this means that the analysis of multiple related cytokines is more informative than 
the measurement of a single cytokine.
In the present study we wished to examine the circulating concentrations of those 
cytokines recognised to have a role in immune function. It was anticipated that the 
cytokines/ chemokines profile would give further information as to the nature of the 
immune response in patients with bladder cancer. We have previously shown that 
circulating cytokine concentrations differ between those patients with and without elevated 
C-reactive protein concentiations using an ELISA system for single cytokines (McKeown 
et al., 2004). In the present study, although the assay system used was capable of 
measuring 21 cytokines at the same time, the sensitivity was limited and the majority of 
samples had undetectable concentrations. The result of this was that there appeared to be 
no significant difference in cytokine concentrations between those patients with and 
without elevated C-reactive protein concentrations.
To date multiplex analysis of cytokines has been almost exclusively limited to cell 
culture supernatants. In terms of the number of peptides and proteins such supernatants are 
much less complex than that of a plasma or serum sample. Indeed, the problems of 
analysing plasma or serum samples have been suggested by De Jager and colleagues (2003) 
who note that when sera are used as the analytical matrix the matrix should be carefully 
monitored for blocking substances such as heterophilic antibodies. Taken together the
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above observations would suggest that there is a need to pre-treat plasma or serum samples 
prior to multiplex analysis of cytokines.
In summary there remain a number of technical challenges to be overcome before 
multiple cytokine analysis can be applied to identify the nature of the immune response in 
patients with a systemic inflammatory response and transitional cell carcinoma of the 
urinary bladder.
I l l
Table 5.1 Clinicopathological characteristics and cytokines/ chemokines profiles according 
to the presence or absence of a systemic inflammatory response in patients with transitional 
cell carcinoma of the urinary bladder.
No systemic Systemic
inflammatory response inflammatoiy response
CRP<1 Omg/1 CRP>1 Omg/1 p-value
(n=31) (n=16)
Age (<65/>65yrs) 9/ 22 6/10 0.559
Sex (male/female) 23/8 11/5 0.696
Stage
(superficial/ invasive) 22/9 9/7 0.318
Grade (G1/G2/G3) 4/ 12/15 3/ 8/5 0.295
ThO cytokines
IL-lb 35 (<5-1465) 35 (<5-1422) 0.917
IL-6 <5 (<5-2586) 6 (<5-173) 0.613
IL-7 <5 (<5-590) <5 (<5-172) 0.915
IL-8 <5 (<5-198) <5 (<5-46) 0.574
IL-12 49 (27-742) 43 (18-760) 0.606
IL-15 <5 (<5-613) <5 (<5-828) 0.800
GM-CSF <5 (<5-4132) <5 (<5-106) 0.516
RANTES 17572 (<5-132605) 19374 (1283-539602) 0.928
Thl cytokines
IL-2 <5 (<5-1960) <5 (<5-1469) 0.279
INF gamma <5 (<5-<5) <5 (<5-17) 0.164
TNF alpha <5 (<5-236) <5 (<5-863) 0.974
IF-10 34 (7-204) 44.5 (23-80) 0.381
MIG <5 (<5-361) <5 (<5-576) 0.55
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continue Table 5.1
No systemic Systemic P value
inflammatory response inflammatory response
Th2 cytokines
IL-4
IL-5
IL-10
IL-13
Eosinophil cytokines 
EOTAXIN
Monocyte/macrophage 
cytokines 
MIP-1 alpha 
MIP-1 beta 
MCP-1
Median (range)
<5 (<5-201) 
<5 (<5-53)
<5 (<5-1216) 
<5 (<5-75)
58 (<5-172)
33 (<5-132)
39 (<5-488) 
120(66-1500)
<5 (<5-166) 
<5 (<5-<5)
<5 (<5-19)
<5 (<5-33)
69.5 (14-219)
36.5 (8-705) 
66 (<5-2044 
137 (63-691)
0.487
0.304
0.907
0.937
0.728
0.253
0.291
0.261
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CHAPTER 6: CONCLUSION
6.1 Introduction
In chapter two, the aims of this thesis were defined as follows;
To investigate the following in patients with transitional cell carcinoma of the urinaiy 
bladder:
1. The prognostic value of the systemic inflammatoiy response.
2. The relationship between the systemic inflammatory response, tumour 
proliferative activity, T-lymphocytic infiltration, COX-2 expression, tumour 
associated macrophage and microvessel density and survival.
3. The relationship between the T-lymphocyte cytokine profile and the systemic 
inflammatory response.
6.2 Summary of the findings
In chapter three, we have shown that in common with those suffering a wide 
variety of solid tumours, patients with transitional cell carcinoma of the urinary bladder 
mount a systemic inflammatory response as evidenced by raised circulating 
concentration of C-reactive protein, independent of tumour-based factors e.g. stage and 
grade.
In chapter four, several findings were observed: there was a strong correlation 
between tumour grade and tumour proliferative index and both were closely associated 
with tumour T-lymphocytic and macrophage infiltrate, microvessel density and COX-2 
expression. In addition, tumour stage, Ki-67 labelling index, macrophage infiltration 
and microvessel density but not T-lymphocytic infiltration or COX-2 expression were 
independently associated with cancer-specific survival. This would suggest that tumom*
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macrophage infiltration is an important host response associated with disease 
progression and poor survival in patients with transitional cell carcinoma of the urinary 
bladder. Moreover, this would suggest that macrophage production, rather than tumour 
production, of interleukin-6 drives the systemic inflammatory response seen in bladder 
cancer.
In chapter five, we anticipated that the cytokine profile would inform as to 
whether a Thl or Th2 response was dominant in patients with bladder cancer.
However, although the assay system used was capable of measuring 14 cytokines at the 
same time the sensitivity was limited and the majority of samples had undetectable 
concentrations. The result of this was that there appealed to be no significant difference 
in cytokine concentrations between those patients with and without elevated C-reactive 
protein concentrations, tumour stage and grade.
In the present studies there ai e a number of potential biases. These include the 
following: that the cohort was retrospective and that both superficial and invasive 
disease patients were studied. However, it is clear that the study cohort was 
representative, in terms of clinical pathological characteristics, of a larger cohort which 
presented to the Glasgow Royal Infirmary between 1992 and 1999. With regard to 
superficial and invasive disease, it would have been better to consider these patient 
groups separately. Moreover, although cancer-specific survival is a strong end-point it 
might have been better to have considered relapse-fi*ee survival in those patients with 
superficial disease. However, to account for such a bias, the patients were stratified 
according to stage in our analysis.
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It is clear from recent studies that bladder cancer is a heterogeneous disease. For 
example, superficial disease differs from invasive disease in that, in the latter, there is 
high incidence of disease recurrence and progression. There are a number of molecular 
differences between these disease states. For example, oncogenes thought to be 
important in the progression of bladder cancer, from superficial to invasive disease, 
include HER2/neu (Miyamoto et al., 2000). Moreover, several investigators have 
shown a positive association between over-expression of epidermal growth factor 
receptor (EGFR) and high-grade, high-stage bladder cancer and poor survival 
(Lipponen et al., 1994). In addition, apoptotic index and Ki-67 labelling index appears 
to conelate with tumour grade and stage (Gonzaiez-Campora et al., 2006). Matrix 
metalloproteinases are intimately involved in tumour-associated degradation of the extra 
cellular matrix and one o f these factors, MMP-9; expression was directly related to 
increasing tumour stage (Guan et al., 2003). However, the functional biological 
relationship between these prognostic factors remains unclear. Such differences could 
be secondary to genetic instability and accumulation of collaborative genetic lesions 
mainly involving p53, retinoblastoma (Rb), and growth factors (Al-Sukhun and 
Hussain, 2003).
6.3 Significance of findings
It would appear that the systemic inflammatory response is an independent 
prognostic factor in patients with bladder cancer. These results are consistent with the 
superior prognostic value o f C-reactive protein compared with tumour T-lymphocytic 
infiltration in patients with primary operable colorectal cancer. One possible 
explanation is that C-reactive protein can be measured with greater accuracy and
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precision than tumour-based factors. Alternatively, it may be that C-reactive protein 
plays a more pivotal role in the tumour-host relationship. Indeed, there is increasing 
evidence that C-reactive protein has prognostic value, independent of the malignant 
potential, in a variety of tumour s. The role of the systemic inflammatory response in 
determining disease-specific smwival in patients with bladder cancer is worthy of 
further study to establish its value as a prognostic index. Such an index would help 
stratify patients into groups at the time of diagnosis and staging into three groups. The 
first is the group with the least chance of recurrence and progression, which will require 
less frequent and shorter period o f follow-up. The middle group would be followed as 
per the standard follow-up schedule (3 monthly cystoscopy for the first year followed 
by 6 monthly for 2 years then annually thereafter for life). The third is the group with 
the highest chance of recurrence and progression, which will require more frequent 
follow-up and more aggressive treatment.
Such a role needs to be verified in a larger prospective study with a mature 
follow-up. The process of assessing these inflammatory markers routinely will require 
some investment in such investigative tools e.g. the use o f quantitative image analysis.
This thesis supports the measurement of C-reactive protein in patients with 
bladder cancer as a prognostic marker. Moreover, the findings in this thesis support 
future study of the use of anti-inflammatory agents e.g. Ibuprofen, as a means of 
modifying the inflammatory response and so perhaps improving survival in patients 
with transitional cell carcinoma of the uiinary bladder.
The observation that there is a coirelation between tumour- grade and tumour 
proliferative index is o f importance. Assessing the tumour proliferative index in 
addition to tumour grade would be useful. This could be a useful tool to identify the
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correct tumour grade especially in grade 2 tumours in which there is a high inter- 
observer difference in grading.
In superficial disease, recurrence and progression would be clinically relevant 
since 70% of patients with superficial disease will have recurrence and of these 50% 
within 2 years ((Zieger et al., 1998). Of these recurrences 20% will progress to an 
invasive disease. Approximately 10% of patients would die from their superficial 
cancer compared with approximately 50% of patients with invasive disease. Therefore, 
in superficial disease, future studies of the prognostic value of markers of the local/ 
systemic inflammatory response should also include recunence and progression as end­
points.
The bladder as a confined compartment, in which high local concentrations of 
the immunotherapeutic agent and effective recruitment o f immune cells can be 
achieved, serves as an ideal target organ for this type of immunotherapeutic approach. 
Thalidomide is associated with high levels of TNF, raised CD4+ and suppresses 
angiogenesis, and studies suggest that the BCG effect on bladder cancer may be through 
TNF (Alexandroff et al., 1999). Therefore, giving intravesical thalidomide may help to 
control the disease and may not have the systemic side effects of thalidomide.
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APPENDIX 2: CLINICOPATHOLQGICAL DATA (CHAPTER 41
There follows the raw data collected for the retrospective study for patients with 
transitional cell carcinoma of the urinary bladder which is discussed in chapter 4. 
Abbreviations Used in Tables 
Treatment Code:
0 = Transurethral resection of bladder tumour + single intravesical mitomycin
1 = Cystectomy
2 = Radical radiotherapy
3 = Intravesical BCG 
Follow-up Code:
0 = Alive
1 = Bladder cancer specific death
2 -  Death due to intercurrent disease
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APPENDIX 3: DATA FROM THE PROSPECTIVE STUDY FOR PATIENTS 
WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER 
DESCRIBED IN CHAPTER 5
There follows the raw data collected for the prospective study for patients with 
transitional cell carcinoma of the urinary bladder which is discussed in chapter 5.
Abbreviations Used in Tables 
Treatment Code:
0 -  transurethral resection of bladder tumour + single intravesical mitomycin
1 = Cystectomy
2 = Radical radiotherapy
3 = Inti'avesical BCG 
IFNG: Interferon gamma
GM-CSF: Granulocyte / macrophage colony-stimulating factor 
TNFA: Tumoui* necrosis factor alpha
RANTES: Regulated on Activation, Normal T Expressed and Secreted 
MIG: Monokine induced by interferon gamma 
MIP: Monocyte inflammatory protein 
MCP: Monocyte chemo-attractant protein
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